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A b st r a c t
The A2780 human ovarian adenocarcinoma cell line was used to establish 
methodologies for the detection and quantitation of ionising radiation- and cisplatin- 
induced apoptosis. Detection of apoptosis in A2780 cells by field inversion gel 
electrophoresis of DNA was found to be reliable and accurate. Apoptosis was 
quantitated using fluorescent end-labelling of DNA fragments by TUNEL/PI staining 
followed by FACs analysis. Cells displaying apoptotic morphology (dense chromatin, 
pyknotic nuclei around the cell margin, apoptotic bodies) when viewed by confocal 
microscopy were found to be those which also displayed increased green fluorescence 
due to TUNEL staining.
A2780 cells engaged apoptosis in response to DNA damage generated by both 
ionising radiation and cisplatin. The DNA of apoptotic A2780 cells degraded in a non- 
random manner to produce DNA fragments of two sizes: one of 50kbp and one of 300- 
lOOOkbp. The DNA did not degrade further to produce intemucleosommal fragments. 
Maximal apoptosis occurred at either 72h or 96h after both cisplatin and radiation.
Ionising radiation-induced apoptosis was reduced in the A2780/cp70 cell line 
compared to A2780 cells. Cisplatin-induced apoptosis was reduced in nine out of ten 
cisplatin resistant cell lines derived in vitro from A2780 cells. A higher level of Bcl-2 was 
observed in A2780/cp70 and this may contribute to the lack of apoptosis seen in these 
cells.
The role of p53 in ionising radiation- and cisplatin-induced apoptosis in A2780 cells 
was investigated using a dominant negative mutant TP5 3 (codon 143, val to ala)- 
transfected cell line, A2780/mp53. A2780/mp53 cells underwent less apoptosis than the 
vector-transfected control cell line after equal doses of cisplatin or ionising radiation.
These results showed that DNA damage caused by cisplatin or ionising radiation 
resulted in cell death by apoptosis in A2780 cells which was reduced in resistant cell 
lines. In addition they indicate a role for functional p53 in the ionising radiation- and 
cisplatin-induced apoptotic responses of A2780 cells.
A b b r e v ia t io n s
ala alanine mm millimetre
APS ammonium persulphate mM millimolar
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b- biotinylated- mg milligram
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CHAPTER 1
In tr o d uc tio n
1.1 Apoptosis
Apoptosis is a morphological phenomenon that occurs as a result of a cell engaging a 
programmed cell death pathway following growth factor deprivation or treatment with 
cytotoxic agents. It occurs as the result of exposure to a wide variety of DNA damaging 
agents, including cisplatin and ionising radiation, in many different cell types (reviewed in 
Kerr et al., 1994). Apoptosis had been observed as early as 1885 when it was referred to 
as chromatolysis (reviewed in Majno and Joris, 1995) but it’s importance was not 
recognised until the early 1970’s when it’s possible role in the regulation of cell 
populations was realised (Kerr et al., 1972; Kerr, 1971).
Apoptosis is under genetic control (Wyllie, 1994) and is a metabolically active 
process. Morphologically, the cell shrinks and becomes denser. The chromatin becomes 
pyknotic and packed into smooth masses around the cell margin. The nucleus then 
breaks up by producing processes containing fragments of chromatin. These processes 
break off to form apoptotic bodies which may be phagocytised by macrophages or 
neighbouring cells (Kerr and Harmon, 1991; Majno and Joris, 1995). Biochemically, the 
DNA is broken down into either large fragments of 50kbp and/or 300-1000kbp 
(Oberhammer et al., 1993) or into smaller 180-200bp intemucleosomal fragments known 
as the DNA ladder (Wyllie, 1980). Apoptotic morphology may also be observed in the 
absence of DNA fragmentation (Sun et al., 1994; Cohen et al., 1992).
1.2 The apoptotic signalling cascade
Apoptosis is the morphological manifestation of a programmed cell death cascade 
which can be divided into several stages. Multiple signalling pathways lead from death- 
inducing extracellular agents to a control and execution stage which triggers the onset of
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morphological changes. Extensive work has been done to elucidate the roles of the many 
proteins which appear to be involved in the control and execution of apoptosis. The 
mammalian BCL-2 gene product is an inhibitor of apoptosis (Reed et al., 1995) and is 
homologous to the ced-9 gene of Caenorhabditis elegans (C. elegans) (Hengartner and 
Horvitz, 1994; Hengartner et al., 1992). The ced-9 gene regulates ced-3 which promotes 
programmed cell death during C. elegans development (Ellis and Horvitz, 1986). The 
ced-3 gene product is homologous to the mammalian ICE-like (interleukin ip converting 
enzyme-like) cysteine protease which is a promoter of apoptosis (Miura et al., 1993).
Overexpression of ICE in mammalian cells induces apoptosis which can be inhibited 
by Bcl-2 (Miura et al., 1993). Bcl-2 is a member of a large family of related proteins 
which regulate apoptosis by forming both homodimers and heterodimers (White, 1996;
Oltvai et al., 1993 and references therein). These include promoters of apoptosis: Bcl-xs,
Bax, Bad, Bikl and Bak (which can also inhibit apoptosis), and inhibitors of apoptosis: 
Bcl-2, B c1-x l , Mcl-1, and E1B 19K. ICE is a member of a large family of related highly 
specific proteases known as caspases reviewed in (Martins and Eamshaw, 1997). 
Cisplatin can induce the expression of ICE in murine and human glioma cells during 
apoptosis (Kondo et al., 1995). Cisplatin-induced apoptosis and ICE overexpression can 
be suppressed by Bcl-2 and Bcl-xL in this model suggesting a role for the ICE/Bcl-2 
signalling cascade in cisplatin-induced apoptosis. The apoptosis observed in this case was 
independent of the p53 status of the cell lines. Ionising radiation-induced apoptosis has 
been found to be associated with increased expression of B c1-xl (Zhan et al., 1996). The 
induction of Bcl-xLby ionising radiation was dependent on normal p53 function. It would 
appear that the ICE/Bcl-2 cascade can be induced by both ionising radiation and cisplatin 
and can trigger apoptosis in either p53-functional or -dysfunctional cell types. In addition
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p53 can down-regulate the expression of Bcl-2 and up-regulate the expression of Bax in 
murine leukemia cells (Miyashita et al., 1994) and is a direct transciptional activator of 
the human BAX gene (Miyashita and Reed, 1995).
1.3 The DNA-damage response
1.3.1 Recognition of damage
In order to repair damage introduced into DNA by agents such as cisplatin the 
lethal adducts must first be identified. This can then facilitate the initiation of a signalling 
pathway which may ultimately lead either to repair and survival, to cell death or to 
tolerance of the damage.
Mammalian proteins have been identified, which can bind to DNA damaged by 
various agents including cisplatin. Human single-stranded DNA binding protein (HSSB, 
now known as RPA) which is involved in mammalian excision repair, binds to DNA 
treated in vitro with cisplatin (Clugston et al., 1992). DNA-cisplatin adducts are also 
recognised and bound by a high mobility group protein, HMG1 (Pil and Lippard, 1992) 
and by SSRP1 (Bruhn et al., 1992). The role of these damage recognition proteins 
(DRP’s) in resistance to cisplatin has been investigated. A higher level of DRP’s was 
seen in a cisplatin-resistant human ovarian tumour cell line compared to the sensitive 
parental cell line (McLaughlin et al., 1993). However there was no difference in the 
binding activity in extracts from tumours of different cisplatin sensitivity (Bissett et al.,
1993).
It has been suggested that signalling pathways are induced following ionising 
radiation damage due to the relaxation of DNA supercoiling, triggered by the DNA 
single strand breaks (Povirk and Painter, 1976). Many genes induced in response to the
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oxidative stress of ionising radiation have been identified, including transcription factors, 
proteases, protease inhibitors and proteins affecting cell proliferation (reviewed in 
Janssen et al., 1993). One of these, the transcription factor p53 is known to accumulate 
following ionising radiation (or cisplatin) treatment of cells in vitro (Brown et al., 1993; 
Kastan et al., 1991; Maltzman and Czyzyk, 1984). The C-terminus of the p53 protein has 
also been shown to bind with increased affinity to DNA damaged by ionising radiation 
(Reed et al., 1995). The role of p53 in the DNA-damage response pathway is discussed 
in greater depth in the following sections.
1.3.2 The role of p53 in the DNA damage response pathway 
1.3.2.1The p53 tumour suppressor protein
The human TP53 gene is approximately 20kb in size and contains 11 exons 
(Lamb and Crawford, 1986). The product of this gene is a protein which contains five 
evolutionarily conserved regions, the first of which is proximal to the amino terminus 
(amino acid residues 13-19) and the other four are clustered centrally, between residues 
100 and 300 (Soussi et al., 1990). These are the DNA binding domains (Cho et al.,
1994). The C-terminus contains the tetramerisation domain (Sturzbecher et al., 1992) 
and nuclear localisation signals which are essential for p53 activity (Shaulsky et al.,
1991). Residues 1-43 of the N-terminus contain the transactivation domain (Unger et al.,
1992).
The p53 protein is a nuclear phosphoprotein (Mx 53,000) of 393 amino acids 
that acts as a tumour suppressor protein. It was discovered as a protein bound to the 
SV40 large T antigen (Lane and Crawford, 1979). The p53 protein can bind DNA at 
certain specific contact points on the protein and is capable of sequence specific binding
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(Kern et al., 1991) which is associated with growth suppression (Pietenpol et al., 1994). 
It is a transcriptional transactivator which can regulate various genes including 
WAF1/CIP1 (Harper et al., 1993; El-Deiry et al., 1993), CYCLING (Okamoto and 
Beach, 1994) mdMDM2 (Wu, 1993; Oliner et al., 1993; Momand et al., 1992). The 
wild-type p53 protein is capable of suppressing the tumorigenic phenotype in a variety of 
cell types (Johnson et al., 1991; Casey et al., 1991; Baker et al., 1990; Finlay et al.,
1989). Certain mutant forms of TPS3, if transfected into normal cells containing wild- 
type p53, cause cellular transformation (Hinds et al., 1989; Eliyahu et al., 1988) and the 
endogenous wild-type p53 can be driven into a mutant conformation (Milner and 
Medcalf, 1991). This causes abrogation of wild-type p53 binding and transactivation 
activities (Kern et al., 1992; Farmer et al., 1992). As mentioned above, p53 accumulates 
in response to ionising radiation and other DNA-damaging agents. This accumulation 
may occur by a post-translational mechanism (Kastan et al., 1991) possibly as a result of 
an increased half-life of the protein leading to enhanced stability. Alternatively it has been 
found that the p53 3’UTR (untranslated region) is involved in translational repression 
which is alleviated following DNA damage by y-irradiation (Fu and Benchimol, 1997).
1.3.2.2 Mutations in TP53
Missense mutation in one allele of TP53 with concomitant loss of 
heterozygosity of the other allele is the most common genetic alteration in human cancer 
(Hollstein et al., 1991; Takahashi et al., 1989; Nigro et al., 1989). Eighty to ninety 
percent of mutations in the TP53 gene are missense mutations leading to a 
conformational change in the protein (Greenblatt et al., 1994). The TP53 gene is one of 
the most frequently encountered genetic alterations in solid tumours (Toma et al., 1992) 
and is found to be mutated in 25-80% of ovarian tumours (Teneriello et al., 1993; Milner
et al., 1993; Kupryjanczyk et al., 1993; Kohler et al., 1993; Okamoto et al., 1991;
Mazars et al., 1991; Marks et al., 1991). The majority of mutations (80-90%) are found 
between codons 100 and 300 which spans the four centrally clustered conserved domains 
(Soussi et al., 1990).
1.3.2.3 p53 and cell cycle arrest
Following routine damage of DNA, cell cycle arrests are thought to be 
implemented in order to allow time for repair before DNA replication (Gl- and S-phase 
arrests) or segregation of chromosomes (G2-phase arrest). The p53 protein is a crucial 
player in the Gl/S cell cycle checkpoint. Following y-irradiation of wild-type p53 cells 
there is a transient induction of the p53 protein which correlates with the Gl arrest 
(Kastan et al., 1991). It was found that p53 could transcriptionally activate the 
WAF1/CIP1 gene (El-Deiry et al., 1993) whose gene product, p2\WAFI/clPI could inhibit 
the Gl cyclin-dependent kinases (Harper et al., 1993). The p2 \WAF1/C1P1 protein is induced 
by exposure to DNA-damaging agents in wild-type p53-containing cells that are 
undergoing p53-dependent Gl arrest (El-Deiry et al., 1994). The ionising radiation- 
induced Gl arrest is completely abrogated in p21 f^ F7/c/P7-deficient cells (Waldman et al.,
1995) demonstrating the absolute necessity for p2\WAFI/CIPI induction in this DNA 
damage response. In addition, neither p53 nor p2 \WAF1/CIPI are required for the ionising 
radiation-induced G2 cell cycle arrest (Levedakou et al., 1995; Mcllwrath et al., 1994) 
demonstrating the specificity for the Gl arrest in this DNA damage response pathway.
The p2lWAFI/CIPJ protein forms a complex with PCNA and GADD45 thereby exerting its 
effects on the Gl cyclin-dependent kinases (Smith et al., 1994; Waga et al., 1994). 
Atematively the p2lWAFI/CJP1 protein may be able to inhibit Gl-S phase transition by 
directly binding the Gl cyclin-dependant kinases (Ogryzko et al., 1997). The p2\WAF1/CJP1
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protein was in fact found to be a universal inhibitor of cyclin-dependent kinases (Xiong 
et al., 1993) however only the p 2 1 ^ v/c//>/-induced Gl arrest is dependent on wild-type 
p53 (Lin et al., 1992; Kuerbitz et al., 1992; Kastan et al., 1991).
1.3.2.4 p53 and apoptosis
When a cell is exposed to a DNA damaging agent it can arrest in either Gl/S or 
G2, presumably to allow the cell time to repair the damage. Alternatively, the DNA 
damaging agent may trigger the cell to enter a cell death pathway. Wild-type p53 is 
required for ionising radiation-induced apoptosis in mouse thymocytes (Clarke et al., 
1993; Lowe et al., 1993). There is growing evidence that this induction of p53- 
dependent apoptosis occurs by a different pathway to the p53-dependent Gl/S cell cycle 
arrest and does not require the induction of p2 \WAF,/CIPI (Friedlander et al., 1996; Ludwig 
et al., 1996; Attardi et al., 1996; Rowan et al., 1996; Haupt et al., 1995). There is 
conflicting evidence for the requirement of p53 transcriptional activation of target genes 
for apoptosis. In some cases it has been found that p53 transcriptional activation is 
dispensable for the induction of apoptosis (Haupt et al., 1995; Wagner et al., 1994; 
Caelles et al., 1994) while on the other hand, specific defects in transcriptional activation 
have been found to correlate with impaired apoptotic function (Ludwig et al., 1996). It 
would seem that the requirement for p53 transcriptional activation is highly dependent on 
the genetic context and on the apoptotic effector.
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1.3.2.5 Loss of p53 function and resistance in ovarian carcinoma cells
Human ovarian adenocarcinoma cells which have been transfected in vitro with 
a mutant TP53 (codon 143, val-ala) lose wild-type p53 function as measured by a loss of 
the DNA damage-induced Gl cell cycle arrest (Brown et al., 1993). These mutant p53- 
containing cells become more resistant to ionising radiation (Mcllwrath et al., 1994) and 
to a variety of other cytotoxic agents (Vasey et al., 1996) as compared with the 
intrinsically sensitive parental cells and cells transfected with vector alone. In addition, 
p53 function was found to correlate with intrinsic radiosensitivity in a panel of cell lines 
which reflected the radiosensitivity of the tumours from which they were derived 
(Mcllwrath et al., 1994). Cells selected in vitro for cisplatin resistance have been shown 
to have increased levels of p53 protein and are dysfunctional for DNA damage-induced 
Gl arrest (Brown et al., 1993). In addition they are cross resistant to ionising radiation 
and multiple chemotherapeutic agents (Vasey et al., 1996; Vasey et al., 1995).
1.4 Cisplatin
1.4.1 Modes of cytotoxicity
Cisplatin (or c/s-dichlorodiammineplatinum(II)) is widely used in the 
chemotherapeutic treatment of ovarian carcinoma (as well as in testicular and head and 
neck carcinoma). Ovarian cancer is the fifth most common type of cancer among females 
in the UK. Treatment of ovarian carcinoma typically involves surgical resection, followed 
by chemotherapy and/or local radiation. Cisplatin’s cytotoxic effects against cells in 
culture are directly related to total platinum binding to DNA (Knox et al., 1986), to 
cisplatin-DNA interstrand crosslinks (Zwelling et al., 1979) and to intrastrand crosslinks
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at the N7 position of adjacent guanine bases (Eastman, 1987; Eastman, 1983). This latter 
adduct is thought to be the main mechanism by which cisplatin exerts it’s cytotoxicity.
1.4.2 Cellular responses to cisplatin
Treatment of cells in vitro with cisplatin causes cell cycle perturbations (Gl/S and 
G2 phase cell cycle arrests) and cell death by apoptosis (Ormerod et al., 1994; Demarcq 
et al., 1992). Cisplatin can induce an increase in accumulation of wild-type p53 protein in 
ovarian tumour cells (Brown et al., 1993) and can thereby lead to increased mRNA 
levels of p53 activated genes such as WAF1/CIP1 (El-Deiry et al., 1993).
1.4.3 Mechanisms of cisplatin resistance
As with most cancer therapies the recurrence of disease is a major consideration. 
Initially sensitive tumours, such as ovarian carcinoma can acquire multidrug resistance 
after exposure to a single agent (Kaye, 1988). This phenomenon is also observed in vitro 
after multiple (Vasey et al., 1996; Hamaguchi et al., 1993; Behrens et al., 1987) or single 
(McLaughlin et al., 1991) exposures to cisplatin. Possible mechanisms of acquired 
cisplatin resistance which may not involve p53 include decreased cisplatin uptake and 
accumulation (reviewed in Gately and Howell, 1993) and increases in glutathione or 
metallothionein levels in resistant cells (reviewed in Andrews and Howell, 1990). A 
genetic mechanism for decreased cisplatin uptake has not been elucidated and in no case 
is the change greater than 50% suggesting that this theory could not fully explain 
acquired cisplatin resistance. Increases in glutathione and metallothionein levels have 
only been observed in cells selected for resistance by chronic exposure to cisplatin 
(Andrews et al., 1990). When 2-3-fold cisplatin-resistant cells were selected from the
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human ovarian carcinoma cell line, 2008, no elevation in glutathione level was observed 
(Andrews et al., 1985). In addition, an increase in metallothionein was not observed in 
cell lines obtained from patients’ tumours that were refractory to cisplatin (Schilder et 
al., 1990). Other mechanisms which may contribute to acquired cisplatin resistance 
include adduct tolerance, increased recognition or repair of cisplatin adducts (see below) 
or loss of some component of the cell death signalling pathway.
1.4.4 DNA repair and cisplatin resistance
Nucleotide excision repair is thought to be the main mechanism by which cells 
remove cisplatin adducts from DNA (Hansson and Wood, 1989; Sibghat-Ullah et al., 
1989). The lines of evidence for differences in adduct removal being the cause of 
resistance however, are contradictory. Some investigators have observed an increase in 
adduct removal in cisplatin-resistant cells compared to their cisplatin-sensitive parental 
lines (Masuda et al., 1990; Eastman and Schulte, 1988). Others have found no 
correlation between cisplatin sensitivity and adduct removal (Shellard et al., 1991; 
Terheggen et al., 1990; Bedford et al., 1988). In addition, in cases where increased 
adduct removal has been seen, the cells are 10- to 100-fold more resistant than the 
parental lines and increases in adduct removal of 3- to 4-fold would not seem to correlate 
with the high levels of resistance. It would seem that differences in DNA repair are 
dependent on both the cell type under investigation and the mode of selection for 
cisplatin resistance. It has been suggested that cisplatin resistance may be due to 
tolerance of cisplatin-DNA adducts and indeed cisplatin-resistant A2780 cells can 
tolerate four times as much cisplatin on their DNA as sensitive cells at equitoxic 
concentrations (Johnson et al., 1994b; Schmidt and Chaney, 1993). One possible 
mechanism of tolerance is by adduct bypass (Mamenta et al., 1994). Another possible
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mechanism is the selective repair of transcriptionally active genes (Zhen et al., 1992). 
Tolerance of resistant cells to cisplatin adducts is concordant with the cells having a 
defect in the signalling pathway that leads to cell death.
1.5 Ionising radiation
1.5.1 Modes of cytotoxicity
Ionising radiation has been used as an adjuvant to surgery, as treatment for non- 
resectable disease or as palliation for advanced ovarian cancer. Postoperative irradiation 
has also been used in cancer therapy. Exposure of cells to ionising radiation results in a 
variety of DNA lesions via the action of free radicals which cause oxidative damage. 
These lesions include DNA base alterations, DNA-DNA and DNA-protein cross-links, 
and single- and double-strand DNA breaks (Ward, 1997). Of these, the double strand 
break is the primary lethal lesion. Double-strand DNA breaks can lead to lethal 
chromosomal aberrations (Phillips and Morgan, 1992) and mammalian cells with 
deficient or delayed double-strand break repair are more sensitive to ionising radiation 
(Jeggo, 1990). There is also some evidence from experiments performed on bovine aorta 
endothelial cells that radiation can induce cell death through hydrolysis reactions in the 
plasma membrane (Haimovitz-Friedman et al., 1994).
Apart from the clinical relevance of studying the response of cells to radiation and 
the acquisition of radio-resistance in vitro, ionising radiation also presents a means of 
introducing lethal lesions into DNA in the form of double strand DNA breaks, the 
cellular reaction to which may be considered without the complicating factor of the 
pharmacokinetics of chemotherapeutic drugs.
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1.5.2 Radiation resistance
Acquired radioresistance can occur in some clinical situations (Miller et al.,
1992) and following selection of cells in vitro for resistance to cisplatin (Britten et al., 
1992; Behrens et al., 1987). The mechanisms by which tumorigenesis confers resistance 
to ionising radiation (McKenna et al., 1990) are thought to include changes in damage 
processing and altered cellular metabolism (reviewed in Powell and Abraham, 1993). 
These mechanisms may be common to those involved in acquired cisplatin and multi­
agent drug resistance.
1.6 Project aims
The aims of the project were:
(i) to determine whether or not cisplatin and ionising radiation are capable of inducing 
apoptosis in ovarian tumour cell lines expressing wild-type p53
(ii) to determine whether or not the apoptosis induced by these agents is dependent on 
p53 in these cells
(iii) to determine whether or not the acquisition in vitro, of cisplatin resistance (and cross 
resistance to ionising radiation) is due to a loss of, or reduction in the apoptotic 
response.
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CHAPTER 2
M aterials a n d  M ethods
2.1 M aterials
2.1.1 Chemicals
Chemicals were obtained from the following companies except where indicated in 
the text:
BDH Chemicals Ltd, Supplied by McQuilken & Co, Glasgow, UK
Gibco BRL, Paisley, Renfrewshire, UK
Pharmacia Biotech, Milton Keynes, Bucks, UK
Sigma Chemicals, Poole, Dorset, UK
Boehringer Mannheim, Lewes, East Sussex, UK
2.1.2 Radiochemicals
(a32P)dCTP for random labelling of DNA for Southern hybridisation was obtained 
from Amersham International pic, Little Chalfont, Bucks, UK.
2.1.3 Equipment
Routine equipment which would be an integral part of any laboratory is not listed.
Flow Cytometer Becton Dickinson, Oxford, UK
Milliblot SDE Electroblotter Millipore, Watford, UK
X-Ray Developer 
UV Crosslinker 
Hybridisation Oven 
Electrophoresis Tanks
Kodak, Cambridge, UK
Stratagene, Cambridge, UK
Hybaid Ltd, Middlesex, UK
Biorad Labs Ltd, Watford, UK; IBI Ltd,
Cambridge, UK
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Luminescence Spectrometer
LS50 Perkin Elmer, Beaconsfield, Bucks.,UK
UV Transilluminator and
Digital Imaging System Appligene, Chester-Le-Street, Co.Durham,UK
2.1.4 Enzymes
Terminal DNA transferase was bought from Boehringer Mannheim. Proteinase K was 
supplied by Gibco BRL.
2.1.5 Size markers
High range pre-stained molecular weight markers (Gibco BRL) were used for SDS- 
PAGE gels.
Hindin digested phage X (IBI, Cambridge, UK) and lOObp DNA ladder (Gibco 
BRL) were used for normal agarose gels.
Full length Lambda DNA (Boehringer Mannheim) and Lambda ladder (Promega, 
Southampton, UK) were used for FIGE gels.
2.1.6 Buffers and solutions
All solutions were made with double-distilled water (ddH20) and stored at room 
temperature, except where indicated.
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Streptavidin-FITC solution
4 x SSC
0.1% Triton X-100 
5pg/ml fluoresceinated-avidin 
5% Marvel (non-fat dry milk) 
(prepared immediately prior to use)
Blocking solution (for Westerns)
1 x Blotto 
5% Marvel 
0.01% v/v Tween-20 
ImMDTT
Blotto(lOx)
500mM Tris pH7.5 
500mM NaCl 
lOmMEDTA
Cacodvlate buffer 
200mM Potassium cacodylate 
2.5mM Tris.HCl (pH6.6)
2.5mM CoCl2 
0.25mg/ml BSA
(prepared immediately prior to use)
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Denaturation buffer
0.5M NaOH 
1.5M NaCl
DNA loading buffer 
30% w/v Glycerol 
0.25% w/v Bromophenol blue 
0.25% w/v Xylene cyanol
Genescreen 
0.5M Na2HP04 
0.5M NaH2P04
High salt lvsis buffer 
500mM NaCl 
1% NP-40 
50mM Tris pH7.5 
ImMDTT (added fresh)
Protease inhibitors (lx, added fresh) 
(Stored at 4°C)
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Hoechst 33258-TNE 
lOmM Tris pH7.6 
5mM NaCl 
2mM EDTA
0. lpg/ml Hoechst 33258 (added immediately prior to use)
Hybridisation buffer 
50mM PIPES (pH6.8)
50mM Na2HP04 
50mM NaH2P04 
lOOmM NaCl 
ImMEDTA 
5% SDS
Lvsis buffer (for DNA from whole cells) 
lOOmM Tris.HCl (pH8.5)
5mM EDTA (pH8)
0.2% SDS 
200mM NaCl
lOOpg/ml Proteinase K (added immediately prior to use)
L buffer (for DNA from agarose pellets) 
lOOmM Tris.HCl (pH7.6) 
lOOmM EDTA (pH8)
1% SDS 
20mM NaCl
1 mg/ml Proteinase K (added immediately prior to use)
Neutralisation buffer 
1M Tris (pH7.4)
1.5M NaCl
Protease inhibitors (lOOx)
0.1 mg/ml aprotinin 
0.1 mg/ml pepstatin 
0.1 mg/ml chymostatin 
0.05M benzamidine 
0.05M PMSF 
0.1 mg/ml leupeptin 
(all stored at -20°C)
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5 x Protein loading buffer
250mM Tris (pH8)
10% SDS 
lOmMEDTA 
50% Glycerol
0.25% w/v Bromophenol blue 
0.25% w/v Xylene cyanol
Phosphate buffered saline (PBS)
0.8% NaCl
0.115% Na2HP04
0.02% KC1
0.02% KH2P04
PBS-T
PBS
0.1% Tween-20
0.5% BSA fraction V (w/v)
(Stored at 4°C)
Running gel buffer 
1.5M Tris (pH8.9)
4% SDS
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Spacer gel buffer
0.5M Tris (pH6.7)
0.4% SDS
20 x SSC (pH7)
3M NaCl
300mM tri-Sodium citrate
TAE(lx)
40mM Tris (pH8)
2mM EDTA 
20mM NaCl 
20mM Na Acetate
Tank buffer (5x)
250M Tris 
4% Glycine 
0.5 SDS
TBEHx) pH8 
89mM Tris borate 
89mM Boric acid 
2.5mMEDTA
20
TE pH8 
lOmM Tris 
ImMEDTA
Transfer buffer 
48mM Tris 
39mM Glycine 
0.037% v/v SDS 
20% Methanol
Wash buffer 
1 xSSC 
5% SDS
A human, ovarian adenocarcinoma cell line obtained from 
R.F. Ozols and T.C. Hamilton, Fox Chase Cancer Center, 
Philadelphia.
A2780cp70 A cisplatin resistant derivative of A2780 isolated after
exposure to the drug for two years.
For a more complete description of A2780 and A2780cp70 see Behrens et al., (1987).
2.1.7 Cell lines
A2780
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A2780/mp53 A2780 clonal cell line transfected with the plasmid pC53-
SCX3 containing mutant TP53 cDNA (codon 143, val to 
ala) expressed from a CMV promoter (Brown et al., 1993)
A2780/v A2780 clonal cell line transfected with the pC53-SCX3
plasmid (vector alone).
A2780/mcpl through 9 Independent, multiple step-selected cisplatin resistant
derivatives of A2780 isolated by exposure to increasing 
concentrations of the drug from lpM to 15jiM (Anthoney 
et al., 1996).
2.1.8 Antibodies and immunological reagents
Mouse monoclonal anti-p53 antibody (Ab-6) was purchased from Oncogene 
Science, Cambridge, UK and was used at a concentration of O.lpg/ml.
Mouse monoclonal anti-Bcl-2 antibody was purchased from DAKO (High 
Wycombe, UK) and was used at a concentration of 4pg/ml.
Anti-mouse Ig horseradish peroxidase conjugate (from sheep) was obtained from 
Amersham International and was used at a 1 : 5000 dilution.
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2.2 M ethods
2.2.1 Preparation of DNA
2.2.1.1 Extraction of DNA for agarose gel electrophoresis
Genomic DNA was prepared from cell monolayers by direct addition of lysis 
buffer followed by isopropanol precipitation, according to Laird et al., (1991).
2.2.1.2 Preparation of DNA for field inversion gel electrophoresis
DNA was prepared for field inversion gel electrophoresis (FIGE) according to 
Sambrook et al., (1989). Cells were seeded into 10cm2 plates at 2.5xl03cells/plate and 
allowed to grow for 3 days. The medium was changed for fresh medium before 
irradiation and at various times after irradiation cells were harvested by trypsinisation and 
resuspended in ice cold PBS at a concentration of 4xl06cells/100pl PBS. After warming 
the cell suspension to 42°C an equal volume of 2% low gelling temperature agarose at 
42°C was added to achieve a final concentration of 2x106 cells/ 100jj.1 1% agarose. The 
agarose plugs were allowed to set at 4°C for lOmin and then lysed in L Buffer containing 
1% SDS and 1 mg/ml Proteinase K for 48h at 50°C.
2.2.1.3 Determination of DNA concentration
DNA concentrations were determined by Hoechst 33258 staining and 
spectrophotometric quantitation using a standard curve of human placental DNA.
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2.2.2 Electrophoresis of DNA
2.2.2.1 Agarose gel electrophoresis
DNA samples and size markers, both in DNA loading buffer, were 
electrophoresed through 2% agarose gels containing 0.5pg/ml ethidium bromide. Gels 
were made by dissolving the appropriate amount of electrophoresis grade agarose in 
TBE. The gels were submerged in TBE and run at 3 V/cm. Electrophoresed DNA was 
visualised using a UV transilluminator and a record of the gel was made using a digital 
imaging system.
2.2.2.2 Separation of DNA by field inversion gel electrophoresis
Approximately 106cells per lane were loaded onto a 1% electrophoresis grade 
agarose gel and the wells capped with 1% low gelling temperature agarose. Lambda 
Ladders and denatured X DNA were run as size markers and untreated HL60 cells used 
as control. FIGE was carried out using a horizontal gel chamber, a 500V power supply 
and an IBI Minipulse Polarity Switching System. The gel was run at 100V in 50mM 
Tris-acetate, pH 7.7 and 0.5mM EDTA for 48h at 4°C with an initial reverse time of 
0.1s; reverse increment, 0.02s and an initial forward time of 0.3s; forward increment, 
0.06s.
2.2.3 Southern transfer of DNA
The DNA was then transferred onto nylon membrane by Southern blotting and the 
membrane hybridised with human and X DNA randomly primed with (a32P)dCTP.
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2.2.4 Preparation of radiolabelled probes
Human double-stranded DNA was randomly sheared using a hypodermic needle 
and labelled with (a32P)dCTP using the Prime-It kit (Stratagene, Cambridge, UK). 
Radiolabelled DNA was separated from unincorporated 32P-labelled nucleotides using 
disposable sephadex G50 NICK columns (Pharmacia Biotech). The specific activity of 
radiolabelled probes was determined by taking a small aliquot (5 pi) and measuring the 
number of disintegrations per minute using a liquid scintillation analyser (Packard, 
Pangboume, Berkshire, UK). Probes were denatured before hybridisation by adding 0.1 
volume of 3M NaOH and leaving for 5min at room temperature. After a 5min incubation 
on ice with 0.05 volume of 1M Tris.HCl (pH 7.5), a 0.1 volume of 3M HC1 was added 
and left for a further 5min.
2.2.5 Hybridisation and washing of Southern blots
Pre-hybridisation of blots was carried out at 65°C in hybridisation buffer.
Following hybridisation overnight at 65°C, filters were washed at 65°C using wash buffer 
until the background level of radioactivity was reduced sufficiently.
2.2.6 Extraction of protein
Cells were washed with PBS, then lysed at 4°C for 15min using high salt lysis 
buffer supplemented with protease inhibitors. The lysate was spun at 13,000rpm for 
15min and the supernatant stored at -70°C.
2.2.7 Determination of protein concentration
Protein content was measured using the Bio-Rad kit method.
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2.2.8 Denaturing gel electrophoresis of protein
Solubilised protein and size markers, were separated by SDS-PAGE on an 8% 
running gel after passing through a preliminary 4% stacking gel, both suspended in lx 
tank buffer.
8% Running gel 
8ml Running gel buffer
8.5ml 30% Acrylamide, 0.8% bis-acrylamide (Severn Biotech, Kidderminster, UK)
3.2ml 1% Polyacrylamide
12.3ml ddH20
120pl 10% APS
15pl TEMED
4% Spacer gel 
3ml Spacer gel buffer
1.6ml 30% Acrylamide,0.8% bis-acrylamide 
1.2ml 1% Polyacrylamide 
4.8ml ddH20  
180pl 10% APS 
15 pi TEMED
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2.2.9 Western transfer of protein
Electroblotting was performed using a semi-dry electroblotter. Immobilon-P 
membrane (Millipore, Bedford, MA) was immersed in methanol and then transfer buffer. 
Six sheets of 3MM Whatman filter paper were sandwiched adjacent to the anode and 
cathode with the membrane and gel layered in between. Transfer took place over lh at 
200mA. After transfer, the gel was stained in Coomassie stain as described below. This 
allowed a visual assessment to be made of the uniformity of the transfer.
2.2.10 Coomassie staining of acrylamide gels
Gels were stained with Coomassie stain (0.2% Coomassie Brilliant Blue R250 in a 
50:50:7 v/v ratio of methanol:H20:glacial acetic acid) for 4 hours and then de-stained 
using a 25:68:7 v/v ratio of methanol:H20:glacial acetic acid overnight.
2.2.11 Immunological detection of protein
Membranes were incubated with blocking solution at 4°C for 4h, probed overnight 
in the same buffer with primary antibody and washed with 0.1% Tween-20 in PBS. Blots 
were incubated in blocking solution with anti-mouse IgG HRP-linked rabbit antibody, 
then washed again in 0.1% Tween-20 in PBS, after which bound complexes were 
visualised by enhanced chemiluminescence (Boehringer Mannheim).
2.2.12 Autoradiography
Membranes were exposed to X-ray film (Fuji, supplied by H. A. West, Clydebank, 
Glasgow, UK) and were developed using a Kodak X-ray developer.
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2.2.13 Tissue culture techniques
2.2.13.1 Aseptic technique
Aseptic manipulations were performed using sterilised glassware in a class II 
microbiological safety cabinet with vertical airflow. Cells were grown at 37°C as 
monolayers in supplemented RPMI 1640 (Rosswell Park Memorial Institute; see below 
for supplements) in the presence of 5% C02. They were stored by freezing in RPMI with 
10% di-methyl sulphoxide (DMSO) in 1ml cryotubes at -70°C and were then maintained 
in liquid nitrogen. Mutant p53 and vector-alone transfected cells were regularly exposed 
to 400pg/ml G418 (Gibco BRL) to confirm the presence of the co-transfected G418 
resistance plasmid.
RPMI
88 ml RPMI 1640 (lOx)
800ml sterile distilled water
26.6ml 7.5%Na(C03)2
10ml lOOmM Na pyruvate
10ml 200mM L-glutamine
lml lMNaOH
100ml foetal calf serum
5ml penicillin / streptomycin (50mg)
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Trypsin 
20ml lOxPE
20ml trypsin (2.5% stock)
160ml sterile distilled water
PE
PBS
ImMEDTA
2.2.13.2 Treatment of cells with cytotoxic agents
Cells were treated on day 2 for clonogenic assays and on day 4 for TUNEL/PI
staining.
2.2.13.2.1 Treatment with ionising radiation
All irradiations were performed using y rays from an Alcyon II Teletherapy 
Unit 60Co source at a dose rate of 2Gy per minute. Control cultures were kept in the 
ante-room of the cobalt source during irradiations. The growth medium was changed 
immediately before treatment and was not changed again during the course of the 
experiment.
2.2.13.2.2 Treatment with cisplatin
Cell cultures were treated with cisplatin from a stock dissolved in DMSO. 
The final concentration of DMSO in culture was 0.01%. Control cultures were treated
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with 0.01% DMSO. Cells were treated for one hour after which, fresh medium was 
added. The medium was not changed again during the course of the experiment.
2.2.13.3 Clonogenic assay
Cells were seeded at lxl03 per 90mm diameter dish on day 1. Colonies were 
grown for 10-14 days after treatment and then stained with 1 x Giemsa stain for 10 
minutes and rinsed with tap water. Colonies of greater than 200 cells were counted.
2.2.13.4 Staining of cells
2.2.13.4.1 Staining with trypan blue
Cells were trypsinised, combined with suspension cells and resuspended in 
PBS containing 0.25% v/v trypan blue prior to counting using a hemocytometer.
2.2.13.4.2 Staining with acridine orange
Cells were trypsinised, combined with suspension cells, fixed in ethanol on 
ice and stored at 4°C. Cells were washed in PBS, dropped onto microscope slides, air 
dried and stained with lpg/ml acridine orange in Vectashield anti-fade mountant H-1000 
(Vector Labs, Peterborough, UK). Coverslips were sealed using nail varnish and the 
slides were stored in the dark at 4°C prior to analysis by confocal microscopy (see 
section 2.2.14.2).
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2.2.14 Microscopy
2.2.14.1 Light microscopy
Light microscopy for routine culture of cells and for haemocytometer counts 
was performed using a Diavert Light Microscope .
2.2.14.2 Fluorescence microscopy
Fluorescence microscopy was used to visualise acridine orange-stained cells 
(see section 2.2.13.4.2) and cells stained by TUNEL (with FITC and PI). Small aliquots 
of TUNEL/PI-stained cells in suspension (20pl) were dropped onto microscope slides, 
air dried and mounted with Vectashield anti-fade mountant H-1000. Analysis of both 
staining procedures was performed on a laser scanning confocal microscope equipped 
with a krypton/argon ion laser. A 488/568nm line excitation filter and dual channel 522 
and 585nm emission filters were used. Image analysis was performed using Bio-Rad 
software.
2.2.15 TUNEL assay
2.2.15.1 Harvesting of cells
Exponentially growing monolayer cells were trypsinised, combined with 
suspension cells and fixed in 1% formaldehyde for 15min. on ice. The cells were 
resuspended in PBS and 70% ethanol (pre-cooled to -20°C) and stored at 4°C prior to 
detection of non-random DNA strand breaks.
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2.2.15.2 Detection of DNA strand breaks
Apoptotic cells were detected as described previously (Gorczyca et al., 1993). 
Cells were rehydrated in PBS and counted using a haemocytometer. Aliquots of 106 cells 
were incubated for 30min. at 37°C with cacodylate buffer containing 5units terminal 
DNA transferase (TdT), 0.5nmoles b-dUTP/106 cells. After washing in PBS cells were 
incubated for 30min. at room temperature in the dark with streptavidin-FITC. After a 
further wash in PBS and 0.1% Triton X-100 cells were resuspended in PBS and stained 
with lOpg/ml propidium iodide (PI).
2.2.15.3 Flow cytometry
Cellular fluorescence was detected using a FACScan flow cytometer (Becton 
Dickinson, Oxford, UK). After FITC staining, cells were washed with PBS and 
resuspended in lOjug/ml of PI in PBS and stored at 4°C until analysis. The red (PI) and 
green (FITC) emissions from each cell were separated and quantified using the standard 
optics of the FACScan. Analysis of data was carried out using the Cell Quest programme 
(Becton Dickinson).
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CHAPTER 3
D evelopm ent  of M ethods for  Confirm ation  
a n d  Quantification  of A poptosis
points and should ensure that all the apoptotic cells in the culture are collected on any 
one occasion.
A2780 cells were irradiated with 20Gy ionising radiation. Unirradiated cells were 
used as controls. The suspension cells were harvested at 24h, 48h and 72h after 
irradiation and DNA was prepared from the total suspension cells collected at these three 
time points as described in section 2.2.1.1. The DNA samples from irradiated and 
unirradiated suspension cells were electrophoresed according to the protocol outlined in 
section 2.2.2.1.
No evidence of intemucleosomal, non-random DNA fragmentation was observed 
in the DNA preparations, whether isolated from the suspension cells of irradiated or 
unirradiated cultures (Figure 3.1). The smallest size of DNA fragment seen under these 
conditions was approximately 23kbp in length, whereas when intemucleosomal DNA 
laddering is observed in apoptotic mammalian cells the smallest size of DNA fragment 
that can be detected is approximately 150-200bp (Walker et al., 1993).
3.2.2 Southern blotting of electrophoresed DNA samples
No DNA laddering was observed by ethidium bromide staining in the above 
samples and therefore it would appear that no apoptosis was occurring. The number of 
apoptotic cells in a culture at any one time may be very low since the execution of 
apoptosis is rapid and the time over which one can detect any one particular apoptotic 
cell may be as little as 30 minutes (Evan et al., 1992) thus resulting in a low yield of 
apoptotic cells. In an attempt to sensitise the electrophoretic detection of DNA from 
apoptotic cells, the same samples as used in section 3.2.1 (DNA extracted from 
suspension cells from unirradiated and 20Gy irradiated A2780 cultures) were 
electrophoresed on a large agarose gel. The DNA was then Southern blotted onto
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Figure 3.1 Agarose gel of DNA from suspension cells of A2780 cultures. Lane 2, 
unirradiated (-) A2780 suspension cells; lane 3, 20Gy irradiated (+) A2780 
suspension cells. Size markers are in lane 1 (100 base pair DNA ladder) and lane 4 
(Hindlll digestion of X  DNA).
2kbp
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Hybond-N nylon membrane and hybridised with randomly-sheared, human DNA which 
was 32p_iabelled by random priming (see sections 2.2.3 to 2.2.5). This allows 
visualisation of the total human DNA that is present on the membrane due to 
hybridisation of the probe to repetitive DNA sequences. Again, no evidence of DNA 
laddering was observed (data not shown).
3.3 Field inversion gel electrophoresis and Southern blotting for 
detection of 50kbp and 300-1OOOkbp DNA fragments
It has been found that only some cell lines undergo non-random intemucleosomal 
DNA laddering during apoptosis. Those that do not may still become apoptotic, however 
in these cases the DNA is degraded in a non-random fashion to produce DNA fragments 
of two sizes: one of 50kbp and the other of approximately 300-1 OOOkbp (Oberhammer et 
al., 1993). Normal agarose gel electrophoresis cannot detect fragments of this size and 
so I used field inversion gel electrophoresis (see section 2.2.2.2) in conjunction with 
Southern blotting and detection of DNA with radiolabelled probe as described above. 
Initially I used DNA extracts from cell cultures however these were susceptible to 
random degradation and shearing during handling resulting in a smear of DNA on the 
autoradiograph. To minimise random shearing I adopted the method of embedding cells 
in agarose plugs before lysing to liberate the DNA. In an attempt to produce more 
quantitative results, total cell cultures (suspension cells and trypsinised, monolayer cells) 
were resuspended in molten agarose at a concentration of 106 cells/50pl. An 
approximately equal volume of 50pl was then loaded in each well (106 cells/well) thereby 
allowing the detection of apoptotic DNA fragments relative to the total amount of DNA 
obtained from the culture.
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Field inversion gel electrophoresis enabled discrimination between genomic DNA 
and 50kbp DNA fragments in irradiated A2780 cells. Figure 3.2 shows an irradiation 
dose-dependent induction of DNA fragmentation in A2780 cells as measured by the 
appearance of 50kbp fragments. It must be stressed that due to the small volumes used 
to resuspend the cells (relative to the size of the cell pellet) this measure of programmed 
cell death is of limited quantitative value and therefore it was necessary to develop a 
protocol to allow detection and counting of apoptotic cells.
3.4 Acridine Orange staining
Many investigators count apoptotic cells by staining with the nucleic acid specific 
stain, acridine orange. Apoptotic cells stained in this way appear small and round with 
brightly stained nuclei due to highly condensed chromatin. In addition, the chromatin 
may be arranged in the characteristic shape of a crescent with a dark shadow along it’s 
outer edge. I stained irradiated A2780 cells with acridine orange (see section 2.2.13.4.2) 
and attempted to score for apoptosis on the basis of differential morphology. A2780 cells 
however, are normally small and round and do not flatten out to any great extent on the 
monolayer. They also did not display a very obvious changed nuclear morphology and it 
was difficult in some cases to distinguish between mitotic and apoptotic cells. For these 
reasons I decided that acridine orange staining would not provide a sufficiently objective 
method for quantitating apoptosis in these cells lines.
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Figure 3.2 FIGE of unirradiated (-), 4Gy and 20Gy irradiated A2780 cells (total cell 
population, 72h after treatment). Lane 1 contains full length, linearised Lambda DNA.
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3.5 Measurement of live cells by trypan blue exclusion
The plasma membranes of apoptotic cells remain intact until the very advanced stages 
of the process and cells are still alive despite being committed to a cell death pathway 
culminating in apoptosis. Trypan blue can only enter cells whose membranes are 
permeable. If the apoptotic cells detach from the monolayer it should be possible to 
determine the number of apoptotic cells in the supernatant of a monolayer culture by 
counting those cells that exclude trypan blue. This method should therefore differentiate 
between cells found in the suspension whose membranes are intact and thereby exclude 
trypan blue (apoptotic cells) and those whose membranes are permeable and which 
thereby stain blue (very late-stage apoptotic cells, apoptotic bodies and cell debris).
Figure 3.3 shows the results of cell counts based on trypan blue exclusion from 
suspension cells of irradiated A2780/v and A2780/mp53 cultures (see section 2.2.13.4.1 
for staining protocol). For the purpose of determining the feasibility of this method, only 
suspension cells were considered and the adherent population (and therefore the total 
population) was not counted. Therefore conclusions can only be drawn on the difference 
between untreated and treated populations of the same cell line. No comparisons can be 
made between the two cell lines based on the percentage apoptotic cells in the total 
populations.
There was approximately a 2 fold higher level of trypan blue excluding A2780/v cells 
in the irradiated culture at 4h after treatment compared with unirradiated cells (Figure 
3.3A). At all other time points however, there was either little difference between 
irradiated and unirradiated A2780/v cells (2h and 52h) or more trypan blue excluding 
cells in the unirradiated control (6h, 36h and 38h).
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Figure 3.3 Number of live cells in supernatant of unirradiated and 20Gy irradiated 
cultures as measured by trypan blue exclusion.
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There were more trypan blue excluding cells in the unirradiated A2780/mp53 culture 
at all time points except at 6h and 26h at which times there were only slightly more 
trypan blue excluding cells in the treated culture (Figure 3.3B).
As a result of later experiments it became apparent that significant levels of ionising 
radiation-induced apoptosis could not be detected in these cell lines at times earlier than 
48h (see Chapter 4, section 4.3 and 4.4) and so this could account for the lack of 
increased trypan blue excluding cells in the suspensions of treated compared to untreated 
cultures. This could not however, account for the higher number of trypan blue 
excluding cells in control cultures at many of the time points. In addition, due to the lack 
of total cell counts and thereby the lack of percentage values it was impossible to judge 
whether this higher level of trypan blue excluding cells in control cultures was significant 
or not.
It would appear that the A2780 cell line and its derivatives are loosely adhering, 
anchorage-dependent cell lines. This may account for the spurious results obtained using 
this method in that some of the cells collected from the suspension of the culture will be 
non-apoptotic, mitotic ‘knock-off cells. These results clearly demonstrate that levels of 
apoptosis cannot be measured simply by counting those trypan blue excluding cells that 
detach from the monolayer. No conclusions could be drawn concerning the ability of 
ionising radiation to induce apoptosis in these cell lines or concerning the differences in 
apoptotic response between the two lines.
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3.6 Fluorescent end-labelling of non-random DNA fragmentation for 
flow cytometric analysis of apoptosis
3.6.1 Theory
Apoptotic DNA fragments can be detected using terminal DNA transferase (TdT) 
to end label DNA strand breaks with a fluorescent tag (see section 2.2.15). The amount 
of DNA fragmentation in individual cells is proportional to the green fluorescent signal 
from the FITC-labelled DNA strands. The apoptotic cells in a population are those in 
which an increased level of green fluorescence is detected. Figure 3.4 shows a typical 
flow cytometry profile of cells labelled in this way. Propidium iodide staining (x-axis) 
detects total DNA and facilitates the visualisation of the Gl, S and G2 populations. 
Figure 3.4B shows A2780 cells which were treated for lh with 40pM cisplatin (also see 
section 5.4). The apoptotic cells, with high green fluorescence (y-axis) can be 
distinguished from the untreated cells with lower green fluorescence. This method is also 
known as TUNEL staining (TdT-mediated b-dUTP nick end labelling).
3.6.2 Controls
A number of controls were performed in order to insure that the staining was 
giving a true measure of apoptosis in the treated cells compared with untreated cells. 
Figure 3.5 shows the flow cytometry dot plots obtained from these controls. A2780 cells 
were found to have no detectable intrinsic fluorescence (A). Staining with TdT alone did 
not confer any fluorescent property on the cells (B) and there was no non-specific 
binding of FITC-streptavidin (C). Untreated cells, when stained with all of the 
components necessary to end-label strand breaks but omitting the propidium iodide (PI) 
did not display any significant FITC fluorescence, as would be expected of healthy cells
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Figure 3.4 An example of a contour plot obtained by TUNELVPI staining followed by 
FACs analysis. Fluorescence from propidium iodide is detected in the FL2 channel (x 
axis) and fluorescence from FITC staining is detected in the FL1 channel (y axis).
A. A2780 cells 72h after no treatment
B. A2780 cells 72h after 40pM cisplatin
C. A2780/cp70 cells 72h after no treatment
D. A2780/cp70 cells 72h after 40pM cisplatin.
These results are discussed in Chapter 5.
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Figure 3.5 Controls for specificity o f fluorescence in TUNEL/PI-stained cells
The plots on the left of each panel display PI fluorescence (FL2-H, x-axis) and FITC 
fluorescence (FL-1, y-axis). The plots on the right display forward light scatter (FCS-H, 
x-axis) which is a measure of cell size and side scatter of laser light (SSC-H, y-axis) 
which is a measure of cell granularity. This latter plot was used to detect the cell 
population which was then gated using the CellQuest package. The gated population 
was used for all subsequent analysis. This means that the cells which were analysed 
were of normal size and abnormally large cells were thereby excluded from the analysis. 
Cells which are dying by apoptosis are either of normal size or smaller. Cells which 
swell may be dying by other modes of cell death such as necrosis. This approach was 
employed as a way of excluding cells which may have been dying by modes of cell 
death other than apoptosis.
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(D). Corresponding cisplatin-treated cells (72 hours after treatment) did exhibit an FITC 
signal as would be expected if apoptotic cells were present (G).
Fluorochromes emit light over a range of wavelengths. When cells are stained with 
two or more fluorochromes the signal from one fluorochrome may overlap with that of 
another. The detector used for the first fluorochrome may detect signal from the second. 
It is important to insure that the FITC detector does not pick up signals from PI (and 
vice versa) leading to the detection of artificially high levels of either FITC or PI 
fluorescence. In cells stained with PI alone, PI fluorescence did not contribute 
significantly to the FITC signal (E and H). Likewise, in treated cells stained with all of 
the components except PI, FITC fluorescence was detected but it did not overlap into 
the range of signals detected by the PI detector (G). Panels F and I show the dot plots 
for untreated and treated cells respectively, stained with all of the components.
To insure that the staining was measuring fluorescence due to apoptosis and not 
due to initial DNA strand breaks caused directly by ionising radiation, trypsinised A2780 
and A2780/cp70 cells were irradiated with 4Gy, put immediately on ice to prevent 
apoptosis from occurring and were fixed and stained. No increase in FITC fluorescence 
was observed in irradiated A2780 or irradiated A2780/cp70 cells compared to their 
respective unirradiated controls. Thus, a dose of 4Gy ionising radiation did not cause a 
sufficient number of strand breaks in either cell line to be detected by TUNEL/PI 
staining.
For analysis the profiles were displayed in contour plot form (as in Figure 3.4) in 
order to distinguish more easily between apoptotic and non-apoptotic cell populations. 
This method proved to be the most reliable and least subjective technique for 
quantitating apoptosis in these cells. Results from ionising radiation- and cisplatin-
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induced apoptosis studies as measured by this method are presented in chapters 4 and 5 
respectively.
3.6.3 Cellular morphology and detection of fluorescent end-labelling by 
microscopy
A2780 and A2780/cp70 cells which were stained using TUNEL/PI were dried onto 
microscope slides and visualised by confocal microscopy (see Section 2.2.14.2). Typical 
fields of view are shown in Figure 3.6. Images were saved and a software program (PC 
Ratio, Beatson Laboratories, Glasgow) was used to measure the total pixel intensity of 
the PI and FITC signals from individual cells. This data was plotted on a dot plot (Figure 
3.7). In Figure 3.6B it can be seen that those regions which visibly stained green (due to 
FITC) seemed to be apoptotic bodies and cells with apparent apoptotic morphology. 
Furthermore it can be seen from Figure 3.7 that the treated A2780 cell population 
contained a higher proportion of cells with increased FITC fluorescence than did the 
untreated A2780 cell population or the A2780/cp70 cell populations (treated or 
untreated). To score the cells by eye would be subjective and time consuming. In 
addition the number of cells that could reasonably be counted would be only 200-300 
cells per slide compared with 15,000 cells that can easily be analysed by flow cytometry. 
Analysis of the TUNEL/PI-stained cells by confocal microscopy confirmed that the cells 
which stained with FITC were analogous to the apoptotic cells and that the staining 
method can be used to distinguish between cells which do and do not undergo apoptosis 
in response to DNA damage.
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Figure 3.6 Photographs oi cells obtained b\ conlocal imaging.
A. A2780 cells 72h alter no treatment
B. A2780 cells 72h alter 20u.M cisplatin
C. A278()/cp7() cells 72h alter no treatment
D. A2780/cp70 cells 72h alter 40liM cisplatin
The arrow s mark cells in the late stages of apoptosis. showing green fluorescence 
due to end-labellinc of DNA strand breaks by T l'N EL (1) and apoptotic bodies
A.
C.
B.
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Figure 3.7 Dot plots displaying the data obtained from confocal image analysis 
of cells shown in Figure 3.6 (72h after cisplatin treatment). Units of fluorescence 
represent total pixel intensity per cell.
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3.7 Conclusions
In summary, the A2780 cell line and it’s derivatives did not undergo detectable 
intemucleosomal DNA laddering in response to ionising radiation (or cisplatin, see 
Chapter 5). Their DNA did degrade to fragments of approximately 50 and 300-1000kbp 
in length which is characteristic of apoptotic cells. To separate these fragments it was 
necessary to subject the DNA preparations to field inversion gel electrophoresis. There 
was clearly a low level of apoptosis occurring and so ethidium bromide staining was 
insufficient to detect the DNA fragments. Thus Southern blotting followed by 
hybridisation of randomly sheared, radiolabelled human DNA was employed as a more 
sensitive method of detection.
The morphology of normal A2780 cells was such that simple staining with acridine 
orange in order to identify and count cells with apoptotic morphology was difficult and 
highly subjective. The loosely adherent nature of the cells also made counting live 
suspension cells by trypan blue exclusion an invalid method for quantitating apoptosis. 
Thus the TUNEL/PI staining method in conjunction with flow cytometry was used as it 
provided a rapid, less subjective measure of apoptosis in large populations of cells.
Field inversion gel electrophoresis and TUNEL/PI staining were subsequently used to 
identify and quantitate ionising radiation- and cisplatin-induced apoptosis in the A2780 
cell line and it’s derivatives and to attempt to determine the extent of the dependence of 
the apoptotic response on functional p53. The results of these studies are reported in the 
following two chapters.
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CHAPTER 4
Ionising  Ra dia tio n -In d u c e d  A poptosis in  H u m a n
Ov a r ia n  Cell Lines
4.1 Introduction and Aims
A2780/cp70 cells are resistant to cisplatin, ionising radiation and multiple 
chemotherapeutic agents compared to the parental A2780 cells as measured by 
clonogenic survival assay (Vasey et al., 1996; Behrens et al., 1987). In addition ionising 
radiation and cisplatin cause an inhibition of DNA synthesis (G1 arrest) and a G2 cell 
cycle arrest in A2780 cells, whereas A2780/cp70 cells only arrest in the G2 phase 
(Brown et al., 1993). Transfection of the A2780 cell line with a dominant negative 
mutant of TP5 3 (codon 143 val-ala) causes an abrogation of the ionising radiation- 
induced G1 arrest (Figure 4.1). In addition these mutant p53 transfectants are more 
resistant to ionising radiation and cisplatin (Vasey et al., 1996; Mcllwrath et al., 1994). 
Vector-alone transfectants are comparable to the parental cell line in terms of their 
sensitivity to these two chemotherapeutic agents and their capability to arrest in the G1 
and G2 phases of the cells cycle. Thus the ionising radiation-induced inhibition of DNA 
synthesis observed in A2780 cells is a p53-dependent cell cycle arrest and the sensitivity 
of A2780 cells to ionising radiation is at least in part due to the presence of a functional 
p53 protein. Both A2780 and A2780/cp70 contain wild type TP53 gene sequence 
(Brown et al., 1993) however it would appear that the p53 protein which is present in 
A2780/cp70 cells is dysfunctional.
I therefore compared levels of ionising radiation-induced apoptosis between the cell 
lines to ask the question: does the ability to engage apoptosis play a role in DNA 
damage-induced cytotoxicity by ionising radiation and to what extent does the apoptotic 
response depend on the presence of functional p53?
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Figure 4.1 Loss of p53 function in mutant TP53 transfectants.
A. Ionising radiation-induced inhibition of DNA synthesis as measured by BrdU 
incorporation into vector alone transfectants (A2780/v) and dominant negative mutant 
p53 transfectants (A2780/mp53)
B. Ionising radiation survival curves for the transfectants as measured by clonogenic 
survival assay
(Reproduced from Mcllwrath et al., 1994)
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4.2 Clonogenic survival of vector alone and mutant p53 transfectants of 
A2780
The clonogenic survival data shown in Figure 4. IB was obtained by irradiating cells 
seeded at a low density of 103 cells per plate (see section 2.2.13.3). The survival curve 
for A2780/mp53 cells is shifted to the right indicating increased resistance of these cells 
to ionising radiation as measured by clonogenic assay. The surviving fractions after 2Gy 
irradiation (SF2Gy) for the two mutant p53-transfected cell lines in Figure 4. IB were 
0.58 and 0.47 (mean=0.53). For the two vector-transfected cell lines the SF2Gy values 
were 0.26 and 0.18 (mean=0.22). This translates as a 2.4-fold resistance to ionising 
radiation in the mutant p53 cells compared to the vector control cells. To measure 
apoptosis by either FIGE or flow cytometry, the cells must be seeded and treated at high 
density (approximately 106 cells per plate or greater at the time of treatment). I therefore 
performed a clonogenic survival assay after irradiation of cells growing at high density 
and compared the SF2Gy values and fold resistance with those obtained from a low cell 
density clonogenic assay.
Exponentially growing cells were irradiated at a density of at least 106 cells per plate. 
The cells were then re-seeded at 103 per plate and colonies were allowed to form. A low 
density clonogenic assay was done in parallel. Figure 4.2 shows the data from these 
clonogenic assays. Plating efficiencies of control cells were 38% for A2780/v and 23% 
for A2780/mp53 in the low density assay and 38% and 28% respectively in the high 
density clonogenic assay. The difference in the plating efficiency of A2780/mp53 cells 
between the two assays most likely reflects a variation in cell counts. It is clear though, 
that in both cases the plating efficiency of A2780/mp53 cells is reduced compared with 
A2780/v cells. Following irradiation at low density (Figure 4.2A) the SF2Gy value for 
A2780/v cells was 0.34 while the SF2Gy for the resistant A2780/mp53 cells was 0.5.
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Figure 4.2 Clonogenic survival curves of irradiated cells.
A. cells irradiated at low density
B. cells irradiated at high density and replated
Error bars represent the standard error of the mean; n=3.
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The surviving fraction of cells irradiated at high density (Figure 4.2B) was lower for both 
A2780/v (SF2Gy=0.1) and A2780/mp53 (SF2Gy=0.21) compared to cells irradiated at 
low density. Cells which have been recently irradiated are perhaps more susceptible to 
the additional stress of trypsinisation than unirradiated cells and while the control cells 
can be trypsinised and replated without significantly affecting subsequent plating 
efficiency, the plating efficiency of irradiated cells may be reduced thereby reducing the 
fraction that form colonies relative to control. The fold resistance of A2780/mp53 
compared with A2780/v cells however, did not differ greatly between the two assays (1.5 
fold resistant at low density and 2 fold resistant at high density). It was therefore valid to 
investigate the role of apoptosis in resistance by irradiating cells at a high density.
4.3 Production of large apoptotic DNA fragments in A2780 and A2780/cp70 
in response to ionising radiation
A2780 and A2780/cp70 cells were irradiated with 4Gy ionising radiation, embedded 
in agarose and lysed (see section 3.3). This dose is equally damaging to both cell types, 
introducing an equal number of strand breaks in both A2780 and A2780/cp70 cells 
(Brown et al., 1993). Figure 4.3 shows the autoradiograph obtained. At 24h and 72h 
after irradiation there was an increase in the amount of the larger (300-1 OOOkbp) DNA 
fragment in A2780 cells compared with unirradiated A2780 cells (lanes 9&10 and 
13&14) and at 48h and 72h there was also an increase in fragments of 50kbp in size in 
the irradiated cells (lanes 11&12 and 13&14). A2780/cp70 cells showed an increase in 
the appearance of 300-1 OOOkbp DNA fragments 48h after irradiation compared with 
controls (lanes 5&6) and a slight increase in the appearance of 50kbp fragments at 72h 
(lanes 7&8). While no firm conclusions could be drawn concerning the quantitation of
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Figure 4.3 Autoradiograph showing results of FIGE of DNA from unirradiated (-) and 
4Gy irradiated (+) A2780 (lanes 9-14) and A2780/cp70 cells (lanes 2-8). The negative 
control (lane 1) is unirradiated HL60 cells. The positive control (lane 2) is the 4Gy 
irradiated A2780 DNA sample shown in Figure 3.2.
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apoptosis based on these results due to slight variations in DNA loading, it would appear 
that the A2780 cells underwent apoptosis more readily than did A2780/cp70 cells in 
response to equally damaging doses of ionising radiation.
4.4 Percentage ionising radiation-induced apoptosis in A2780 and 
A2780/cp70
A2780 cells were irradiated with either 2Gy or 4Gy ionising radiation and 
A2780/cp70 cells were irradiated with 4Gy. This approach was used to compare the 
responses of the two cell lines to equally damaging doses of irradiation (4Gy) and to 
compare the effect of doses which produced approximately equal surviving fractions of 
0.2 as measured by clonogenic assay (2Gy for A2780 and 4Gy for A2780/cp70, Brown 
et al., 1993). In order to disrupt the cells as little as possible throughout the time course, 
no medium changes were performed. Cells were detected by TUNEL and propidium 
iodide staining (see Section 2.2.15). Figure 4.4 shows photographs of control and 
irradiated cells acquired using confocal microscopy. Typical apoptotic morphology 
(condensed chromatin and apoptotic bodies) and increased FITC fluorescence (DNA 
fragmentation) can be seen in the irradiated A2780 cells (Panels B and C).
The stained cells were detected by flow cytometry and the data for four repeat 
experiments (three repeats for 2Gy irradiated A2780) is shown in Figure 4.5. There was 
a low background level of apoptosis in untreated cells. The high level of apoptosis seen 
in unirradiated A2780 cells at 72h was not consistently observed but was due to a high 
percentage of apoptotic cells in the control of 1 out of 4 repeat experiments.
After irradiation of both cell lines with 4Gy (inducing equal initial damage in each 
line) apoptosis was 5 fold higher in A2780 compared with A2780/cp70 at 24h and 48h. 
Apoptosis was 6 fold higher in A2780 compared with A2780/cp70 at 72h and 7 fold
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Figure 4.4 Confocal microscopy images of A2780 and A2780/cp70 cells stained by 
TUNEL/PI for How cytometric detection of apoptosis 
A A2780 cells 72h after no treatment
B A2780 cells 72h after 2Gy ionising radiation
C A2780 cells 72h after 4Gy ionising radiation
D. A2780/cp70 cells 72h after no treatment
E. A2780/cp70 cells 72h after 4Gy ionising radiation.
Apoptotic cells are those with green staining due to end labelling of DNA strand breaks 
by the TUNEL method Apoptotic morphology is visable in the ionising radiation-treated 
A2780 cells 1, pyknotic nuclei with condensed chromatin around the nuclear margin, 2, 
cells with fragmented chromatin within their nuclei; 3, apoptotic bodies
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#
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Figure 4.5 Percentage ionising radiation-induced apoptosis in A2780 (solid lines) and 
A2780/cp70 cells(dotted lines) as measured by TUNEL/PI staining and FACs analysis. 
Error bars represent the standard error of the mean of at least three duplicate 
experiments.
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higher at 96h after 4Gy. Approximately the same fold increases in apoptosis (5 fold) 
were observed in A2780 cells at 24h and 48h after 2Gy ionising radiation compared 
with 4Gy irradiated A2780/cp70 cells (equitoxic doses). At both 72h and 96h after 
equitoxic doses of irradiation apoptosis was 2 fold higher in A2780 compared to 
A2780/cp70. It would therefore appear that A2780/cp70 cells have a reduced ability to 
engage apoptosis in response to ionising radiation compared with A2780 cells, even 
after a dose of 4Gy which produces colony forming efficiency equal to that for 2Gy 
irradiated A2780 cells.
The differences in apoptosis induction between the two cell lines were tested for 
statistical significance using the Students /-test. The statistical tests were performed by 
pooling the data from the 72h and 96h time points which, in the majority of 
experiments, were the time points at which the maximal levels of apoptosis were 
observed. The P values calculated using this test are presented in Table 4.1. The same 
criteria for analysis were employed for the statistics presented in Tables 4.2 (page 65) 
5.1 (page 74) and 5.2 (page 77).
Since it has been shown that in some cells a functional p53 protein is required for 
apoptosis (Clarke et al., 1993; Lowe et al., 1993) and A2780/cp70 cells appear to 
contain a dysfunctional p53 protein as measured by a lack of radiation-induced G1 
arrest, it is possible that the reduced ability of A2780/cp70 cells to engage apoptosis in 
response to ionising radiation is as a result of this p53 dysfunction.
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Table 4.1. P values calculated using the Students /-test: 
Irradiated A2780 v irradiated A2780/cp70
TEST P VALUE
A2780 NT
V 0.095*
A2780 2Gy
A2780 NT
V 0.001**
A2780 4Gy
A2780 2Gy
V 0.046**
A2780/cp70 4Gy
A2780 4Gy
V 0.003**
A2780/cp70 4Gy
NT, No treatment
* Statistically significant at a level of P<0.1 
** Statistically significant at a level of P<0.05
4.5 Is ionising radiation-induced apoptosis dependent on the presence of 
functional p53?
In order to investigate the role of functional p53 protein in the ionising radiation- 
induced apoptotic response I performed similar experiments to those described in 
sections 4.3 and 4.4 using the vector-alone and mutant p53 transfectant cell lines.
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4.5.1 Field Inversion Gel Electrophoresis of irradiated A2780/v and 
A2780/mp53 cells
Figure 4.6 shows the pattern of DNA fragmentation observed in A2780/v and 
A2780/mp53 cells after 4Gy ionising radiation. At 72h after irradiation there was an 
increase in the amount of the larger (300-1000kbp) DNA fragments in A2780/v cells 
compared with unirradiated A2780/v cells (lanes 6&7). At 48h and 72h there was an 
increase in fragments of 50kbp in size in the irradiated cells compared with controls 
(lanes 4-7) much the same as was seen in irradiated A2780 cells. A2780/mp53 cells 
showed an increase in the appearance of 300-1000kbp DNA fragments 72h after 
irradiation compared with controls (lanes 12&13). The mutant p53 transfected cells also 
displayed an increase in the appearance of 50kbp fragments in irradiated cells compared 
with controls at all three time points (lanes 8-13). Thus it would appear that quite a high 
level of apoptosis-associated DNA fragmentation was occurring in A2780/mp53 cells, 
however the autoradiographic signal from the wells becomes progressively higher 
moving from left to right across the gel suggesting that the DNA loading was not 
consistent for all the wells or, much more likely, that the DNA was unevenly blotted onto 
the nylon membrane. Nevertheless, there was a high level of DNA fragmentation in the 
radioresistant cell line. It is clear that the expression of a dominant negative p53 in the 
wild type p53 background of A2780 cells did not completely abolish the apoptotic 
response.
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Figure 4.6 Autoradiograph showing results of FIGE with DNA from unirradiated (-) 
and 4Gy irradiated (+) A2780/v (lanes 2-7) and A2780/mp53 cells (lanes 8-13). The 
positive control (lane 1) is the 4Gy irradiated A2780 DNA sample shown in Figure 
3.2.
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4.5.2 Percentage ionising radiation-induced apoptosis in A2780/v and 
A2780/mp53 cells
TUNEL/PI staining and analysis by flow cytometry gave a much clearer picture of 
the levels of apoptosis in the transfected cell lines. For the purpose of this experiment 
both cell lines were irradiated with an equally damaging dose of 4Gy. Figure 4.7 shows 
the data from four repeat experiments. Apoptosis was 3 fold higher in A2780/v than in 
A2780/mp53 at 24h after 4Gy ionising radiation however the level of apoptosis in both 
cell lines was very low at this time. No difference in apoptosis was observed at 48h after 
irradiation however apoptotic cells were detected in both cell lines. At 72h after 
irradiation apoptotic cells constituted 14% of the total A2780/v cell population 
compared with 4% of the A2780/mp53 cells and at 96h apoptotic cells constituted 20% 
of the A2780/v population and 8% of the A2780/mp53 cell population. This translates to
3.5 fold and 2.5 fold higher apoptosis in irradiated A2780/v cells compared with 
A2780/mp53 cells at 72h and 96h respectively. The data from the 72h and 96h time 
points were used to test for a statistically significant difference in apoptosis levels 
between the two cell lines. As shown in Table 4.2 4Gy of ionising radiation induced 
significantly more apoptosis in the vector alone transfectants than in the mutant p53 
transfectants (P=0.026).
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Figure 4.7 Percentage ionising radiation-induced apoptosis in A2780/v (solid lines) 
and A2780/mp53 cells (dotted lines) as measured by TUNEL/PI staining and FACs 
analysis. Error bars represent the standard error of the mean of at least three duplicate 
experiments.
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Table 4.2 P values calculated using the Students /-test: 
Irradiated A2780/v v irradiated A2780/mp53 
(See page 59 for details of statistical analysis)
TEST PVALUE
A2780/v NT
V 0.001**
A2780/v 4Gy
A2780/v 4Gy
V 0.026**
A2780/mp53 4Gy
NT, No treatment
** Statistically significant at a level of P< 0.05
Thus transfection of A2780 cells with a dominant negative mutant of TP 5 3 not only 
causes an abrogation of the radiation-induced G1 arrest but also renders the cells more 
resistant to ionising radiation, which is manifested in a reduction in the ability of the 
cells to engage radiation-induced apoptosis. This demonstrates that ionising radiation- 
induced apoptosis in the A2780 cells is dependent at least in part on wild type p53 
function.
4.6 Conclusions
Results from FIGE and TUNEL/PI staining demonstrated that A2780 cells apoptosed 
in response to ionising radiation. This response was most evident at 72h and 96h after 
irradiation. A2780/cp70 cells did not completely lose their ability to apoptose but did so 
to a much lesser extent than did A2780 cells. The increased apoptosis in A2780 cells 
compared with A2780/cp70 was seen even when the two cell lines were treated with
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equitoxic doses of irradiation, suggesting that the radioresistant A2780/cp70 cells are 
inherently less able to engage apoptosis than are the radiosensitive A2780 cells.
Transfection of a dominant negative mutant of TP53 (codon 143, val-ala) into A2780 
cells caused a reduction in the ability of the cells to engage apoptosis at 72h and 96h 
after irradiation compared with cells containing wild-type p53. There was no difference 
in the levels of apoptosis between the two cell lines at 24h and 48h after irradiation. The 
apoptosis observed in A2780/mp53 cultures may be due to the fact that it retains it’s 
wild-type p53 background whilst overexpressing a transfected dominant negative p53 
protein and so may retain some transcriptional transactivation activity and an ability to 
undergo p53-dependent apoptosis. It is also possible that some of the p53 protein 
present in A2780/mp53 cells as a result of the transfection may be able to transiently or 
otherwise take on a wild type conformation so enabling the cells to undergo a low level 
of p53-dependent apoptosis. This however, would not explain the change in kinetics of 
the apoptotic response to ionising radiation in A2780/mp53 cells compared to A2780/v 
cells. It is possible though, that the change in kinetics may reflect the alteration in cellular 
metabolism which can result from the overexpression of an exogenous protein or 
transfection of exogenous DNA. The plating efficiency of A2780/v cells was comparable 
to that of the parental A2780 cell line. A2780/cp70 cells had a slightly higher plating 
efficiency than A2780 cells however A2780/mp53 cells, overexpressing the mutant p53 
protein had a reduced plating efficiency compared with vector-alone transfectants (and 
A2780 and A2780/cp70 cells). This would suggest that, rather than the transfection of 
exogenous DNA, it may be the overexpression of exogenous protein that could be 
causing a disruption in the metabolism of A2780/mp53.
It was clear that wild-type p53 expressing A2780/v cells underwent more ionising 
radiation-induced apoptosis than mutant p53 expressing A2780/mp53 cells. Thus there
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was a correlation between loss of p53 function, increased resistance to ionising radiation 
and a reduction in the ionising radiation-induced apoptotic response in A2780 cells.
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CHAPTER 5
ClSPLATIN-lNDUCED APOPTOSIS IN HUMAN OVARIAN
Cell L ines
5.1 Aims
The A2780/cp70 cell line was derived from A2780 cells by multiple exposures to 
cisplatin up to a maximum concentration of 70pM. I assessed the apoptotic response of 
both cell lines to cisplatin to determine if a reduction in the ability of the cells to engage 
apoptosis contributes to the reduction in sensitivity to cisplatin of A2780/cp70 
compared to the parental cell line. I measured cisplatin-induced apoptosis in the 
A2780/v and A2780/mp53 cell lines to determine the effect of overexpression of mutant 
p53 in the cells on their ability to apoptose.
Further cisplatin resistant derivatives of A2780 (see section 2.1.7) were used to 
determine the uniformity of reduced ability to engage apoptosis following acquired 
cisplatin resistance in multiple cell lines. A possible role for Bcl-2 in apoptosis in this 
cell line model was also investigated.
5.2 Lack of DNA laddering in A2780 and A2780/cp70 cell lines in 
response to cisplatin
Figure 5.1 shows the ethidium bromide gel of A2780 and A2780/cp70 cells treated 
with 40pM cisplatin, lysed in agarose and electrophoresed. The vast majority of the 
DNA remained in the wells and there was no detectable intemucleosomal laddering in 
the cisplatin treated cells (see long exposure photograph, bottom panel, Figure 5.1). The 
short exposure photograph (top panel, Figure 5.1) revealed the presence of large sized 
DNA fragments which were more abundant in treated A2780 cells at 48h, 72h and 96h 
after cisplatin treatment compared with controls. There was also a slightly increased 
abundance of these large DNA fragments in A2780/cp70 cells 96h after treatment. As 
was the case after exposure to 4Gy ionising radiation (see Chapter 3, section 3.2.1)
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Figure 5.1 Photograph of an ethidium bromide stained agarose gel showing 
electrophoresed A2780 and A2780/cp70 DNA after either no treatment (-) or after a 
lh exposure to 40pM  cisplatin (+). The upper panel shows a short exposure of the gel 
and includes the wells. The lower panel shows a longer exposure with the wells 
removed for clarity.
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A2780 and A2780/cp70 cells did not produce intemucleosomal DNA ladders after 
treatment with 40pM cisplatin. To further elucidate the pattern of DNA degradation in 
the two cells lines in response to cisplatin the same DNA preparations as used here were 
subjected to field inversion gel electrophoresis.
5.3 Production of 50kbp and 300-1000kbp DNA fragments in A2780 and
A2780/cp70 by cisplatin
Field inversion gel electrophoresis was used to resolve the large sized DNA fragments 
observed in Figure 5.1. The same DNA samples as shown in Figure 5.1 were used.
Figure 5.2 shows the autoradiograph of the field inversion gel. DNA damage by cisplatin 
(in addition to that caused by ionising radiation; see section 3.3 and section 4.3) was 
capable of inducing the production of the 50kbp and 300-1000kbp DNA fragments, 
characteristic of apoptosis in these cell lines. At all the times investigated (48h, 72h and 
96h) there was more non-random DNA fragmentation in 40pM cisplatin-treated A2780 
cells compared with untreated A2780 cells. Substantially more non-random DNA 
fragmentation was observed in cisplatin-treated A2780 cells than in cisplatin-treated 
A2780/cp70 cells. Indeed, no increase in DNA fragmentation was observed in 
A2780/cp70 cells 48h and 72h after 40pM cisplatin exposure and only a very slight 
increase in fragmentation compared with control A2780/cp70 cells was observed 96h 
after treatment.
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Figure 5.2 Autoradiograph of a field inversion gel showing A2780 DNA (lanes 4-9) 
and A2780/cp70 DNA (lanes 10-15) after either no treatment (-) or after a lh 
exposure to 40pM cisplatin (+). DNA preparations are the same as those used in 
Figure 5.1.
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5.4 Percentage apoptosis induced by cisplatin in A2780 and A2780/cp70
Cisplatin-induced apoptosis was determined by comparing A2780 cells treated with 
20pM and 40pM concentrations of the drug with 40pM cisplatin-treated A2780/cp70 
cells. This allowed a comparison of the effects of the same dose (40pM cisplatin) on 
each of the cell lines and of the effects of doses which introduce similar levels of total 
cisplatin lesions in each cell line (20pM cisplatin in A2780 cells and 40pM cisplatin in 
A2780/cp70 cells, Johnson et al., 1994a).
Upon quantitating the percentage of A2780 cells which apoptose after cisplatin 
treatment it was found that there was a degree of inter-experimental variation. This 
variation could have been due to differences between batches of cisplatin (three different 
batches were used). Other possible sources of experimental variation are differences in 
the amount of drug presented to the cells on any one occasion, differences in the length 
of exposure to the drug and variation in growth medium.
It can be seen from Figure 5.3 that a concentration of 40pM cisplatin did not induce 
substantial levels of apoptosis in A2780/cp70 cells at the times examined. High levels of 
apoptosis were induced by both 20pM and 40pM cisplatin in A2780 cells (see Table 5.1 
for statistical analysis). It has been shown that 20pM cisplatin introduces the same 
amount of platination into A2780 cells as does 40pM cisplatin into A2780/cp70 cells 
(Johnson et al., 1994a). As shown in Table 5.1 there was significantly more apoptosis 
induced in A2780 cells by 40pM cisplatin than there was in A2780/cp70 cells treated 
with the same concentration of the drug (P=0.005). The difference in apoptosis between 
the two cell lines treated with equally damaging concentrations of the drug was 
marginally statistically significant (P=0.071). This suggests that in A2780/cp70 cells the
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Figure 5.3 Percentage cisplatin-induced apoptosis in A2780 and A2780/cp70 cells as 
measured by TUNEL/PI staining and FACs analysis. Error bars represent the standard 
error of the mean of at least three duplicate experiments.
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cisplatin-DNA lesions were less capable of triggering an apoptotic response than in the 
parental cell line.
Table 5.1 P values calculated using the Students /-test:
Cisplatin treated A2780 v cisplatin treated A2780/cp70
(See page 59 for details of statistical analysis)
TEST P VALUE
A2780 NT
V 0.037**
A2780 20jjM
A2780 NT
V 0.001**
A2780 40pM
A2780 20pM
V 0.071*
A2780/cp70 40]uM
A2780 40pM
V 0.005**
A2780/cp70 40pM
NT, No treatment
* Statistically significant at a level of P<0.1 
** Statistically significant at a level of P<0.05
One of the three batches of cisplatin used in the above experiments induced a very high 
level of apoptosis in A2780 cells (about 80% at 72h and 96h) and so the same batch of 
cisplatin was used again to investigate the extent to which experimental variation, as 
opposed to cisplatin batch variation, was contributing to the different levels of apoptosis 
observed in A2780. The cells again showed a very high level of apoptosis (65%) but 
only at 96h, so it would appear that the measurement of cisplatin-induced apoptosis is
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sensitive to both variations between drug batches and to the variations which inevitably 
occur when treating cells with a drug, such as cisplatin, which does not readily dissolve 
in aqueous solution.
Despite the variations in absolute levels of apoptosis in A2780 cells it was clear that 
upon treatment of A2780 and A2780/cp70 with either equal concentrations of cisplatin 
or with concentrations which introduce equal amounts of DNA damage into the two cell 
lines more apoptosis was induced in the A2780 cell line. Only limited conclusions can be 
drawn on the kinetics of cisplatin-induced apoptosis. A statistically significant level of 
apoptosis was not observed as early as 24h. Maximal apoptosis in A2780 cells was 
observed at 72h after treatment in two out of four experiments and at 96h in the other 
two cases.
5.5 Is cisplatin-induced apoptosis dependent on functional wtp53 in
A2780 cells?
A2780/v cells were treated with 20pM and 40joM cisplatin and the levels of apoptosis 
observed were compared with the levels of apoptosis seen in 40pM cisplatin-treated 
A2780/mp53 cells.
The level of apoptosis detected in control cultures at all time points was less than 1%. 
Cisplatin-induced apoptosis appeared to be dose dependent in A2780/v cells (Figure 
5.4). A higher percentage of apoptotic cells was observed in 40|iM cisplatin-treated 
A2780/v cell cultures than in 20jiM cisplatin-treated cultures (especially at 96h after 
treatment). Maximal apoptosis occurred in A2780/v cultures at 96h after treatment with 
both concentrations of cisplatin (18% apoptosis in 20pM cisplatin-treated cultures and 
42% apoptosis in 40pM cisplatin-treated cultures). The percentage of apoptotic cells
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Figure 5.4 Percentage cisplatin-induced apoptosis in A2780/v and A2780/mp53 cells 
as measured by TUNEL/PI staining and FACs analysis. Error bars represent the 
standard error of the mean of at least four duplicate experiments.
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observed in 40pM cisplatin-treated cultures was greater in the A2780/v cell line than in 
A2780/mp53 cell line at all four time points. This increased level of cisplatin-induced 
apoptosis in the wild-type p53 cells was marginally statistically significant (P=0.065, 
see Table 5.2). A similar pattern of increased cisplatin-induced apoptosis in A2780/v 
was observed when 20pM cisplatin-treated A2780/v cells were compared with 40pM 
cisplatin-treated A2780/mp53 though this trend was not statistically significant.
Table 5.2 P values calculated using the Students /-test:
Cisplatin treated A2780/v v cisplatin treated A2780/mp53
(See page 59 for details of statistical analysis)
Test P value
A2780/vNT
V 0.005**
A2780/v20pM
A2780/v NT
V 0.008**
A2780/V 40p,M
A2780/v 20pM
V 0.433
A2780/mp53 40pM
A2780/V 40pM
V 0.065*
A2780/mp53 40pM
NT, No treatment
* Statistically significant at a level of P<0.1 
** Statistically significant at a level of P<0.05
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5.6 Cisplatin-induced apoptosis in multiply selected cisplatin resistant cell 
lines
It is clear thus far that the acquisition of cisplatin resistance and the concomitant 
acquisition of ionising radiation resistance manifested in A2780/cp70 cells is, at least 
partly, mediated by a reduction in the ability of cells to engage apoptosis. To determine if 
this was a common characteristic of acquired cisplatin resistance in A2780 cells I 
measured the cisplatin-induced apoptotic response in nine other cell lines (A2780/mcpl- 
9, see Table 5.3). These lines were derived by selecting A2780 cells for resistance to 
multiple exposures of increasing concentrations of cisplatin (see section 2.1.7 and 
Anthoney et al., 1996). These cell lines were maintained, as were A2780/cp70 cells, 
without further selective pressure from cisplatin exposure. Eight out of the nine cells 
lines had substantially reduced apoptotic responses to 40pM cisplatin compared with the 
parental A2780 cells. In four of the lines (A2780/mcp2, 3, 4 and 8) a high fold resistance 
(greater than or equal to 3.5 fold more resistant to cisplatin compared with A2780 cells) 
correlated well with a low apoptotic response (less than 2% apoptosis 72h after 40pM 
cisplatin for lh). A2780/mcpl, 5 and 6 cell lines had a lower fold resistance (between 1.5 
and 2.5 fold more resistant to cisplatin than the parental cell line) and had intermediate 
levels of apoptosis of 4%, 8%, and 7% respectively. The majority of these cell lines had 
also lost p53 function as measured by lack of an ionising radiation-induced G1 cell cycle 
arrest. Two of the cell lines were more unusual. One (A2780/mcp9) had a very low 
apoptotic response of 1% and yet was only 1.5 fold more resistant than the parental line.
It is possible that in this cell line, the maximal level of apoptosis was occurring at a 
different time. The other line (A2780/mcp7) retained a high apoptotic response (20%) 
whilst being 3 fold more resistant to cisplatin than A2780 cells.
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Table 5.3 Apoptosis in multiply selected cisplatin resistant derivatives of A2780. 
Percentage apoptosis was measured 72h after 40pM cisplatin by TUNEL/PI staining and 
FACs analysis. Fold resistance was determined by clonogenic assay by D. A. Anthoney. 
G1 arrest data was also acquired by D. A. Anthoney and was determined as the 
percentage of cells in S phase 24h after 2Gy ionising radiation.
CELL LINE FOLD
RESISTANCE
% CISPLATIN 
APOPTOSIS
G1 ARREST
A2780 1 22 0.54
A2780/CP70 5 1 1.05
A2780/MCP1 1.5 4 0.94
A2780/MCP2 3.5 2 1.03
A2780/MCP3 5 1 0.98
A2780/MCP4 4 1 1.2
A2780/MCP5 2 8 0.62
A2780/MCP6 2.5 7 1
A2780/MCP7 3 20 0.64
A2780/MCP8 3.5 1 0.82
A2780/MCP9 1.5 1 0.71
The above values for cisplatin induced apoptosis were obtained after cells had been 
grown in culture for approximately two months (20 passages) following isolation. I also 
measured the apoptotic response of three of the cell lines shortly after isolation (passage 
5) and again approximately 20 passages later. Shortly after isolation A2780/mcpl and 
A2780/mcp5 retained a degree of the apoptotic response observed in the parental line 
(Table 5.4). A2780/mcpl had already lost the p53-dependent G1 arrest in response to 
ionising radiation while A2780/mcp5 had retained this response. After expansion in 
culture their ability to engage apoptosis in response to cisplatin was severely
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compromised. In addition loss of the apoptotic response in A2780/mcp5 cells correlated 
with loss of the p53-dependent G1 arrest. Therefore following initial selection for 
resistance to cisplatin there was a further pressure for selection being exerted in these 
two cell lines in the absence of cisplatin. Table 5.4 also shows the percentages of 
apoptotic A2780/mcp7 cells under the same conditions. These cells did not lose the 
ability to undergo apoptosis and retained the p53-dependent, ionising radiation-induced 
G1 arrest.
Table 5.4 Loss of apoptotic response of cisplatin resistant cells in culture. Levels of 
apoptosis were determined 72h after 40pM cisplatin. The data for G1 arrest is the 
percentage of cells in S phase 24h after 2Gy ionising radiation and was acquired by D. A. 
Anthoney.
CELL LINE PASSAGE G1 ARREST % APOPTOSIS
A2780 5 0.54 23
25 0.56 22
MCP1 5 0.94 7
25 0.84 1
MCP5 5 0.62 13
25 1.15 4
MCP7 5 0.64 22
25 0.69 18
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5.7 Proteins levels of p53 and Bcl-2 in A2780, A2780/cp70, A2780/v and 
A2780/mp53
Bcl-2 has been shown to play a protective role in some cell types, in favour of cell 
survival (Hockenbery et al., 1990). Figure 5.5 shows the levels of p53 protein and Bcl-2 
protein in whole cell extracts from the A2780 cell line and from some of its* derivatives. 
The anti-human p53 antibody used, cross reacts with both wild-type and mutant p53 
protein. As has been shown previously (Brown et al., 1993) wild-type p53 protein 
accumulates in A2780 cells (compare lanes 2 and 3) and in A2780/cp70 cells (compare 
lanes 4 and 5) 24h after 4Gy irradiation. A2780/v transfectant cells behaved similarly to 
the parental cell line (lanes 8 and 9). A2780/mp53 cells contained a constitutively higher 
level of p53 protein as would be expected from a cell line expressing protein from a 
transfected mutant TP53 gene. Following irradiation of A2780/mp53 cells the p53 
protein accumulates, probably due to stabilisation of the endogenous wild-type p53.
Bcl-2 protein was only observed in extracts from A2780/cp70 cells and was not 
detected in the parental line or in its’ transfected derivatives. This lack of detection may 
indicate that the Bcl-2 protein is highly unstable in A2780 but is more likely to be due to 
limited sensitivity of the experimental protocol. Bcl-2 protein has been found to be 
expressed in A2780 cells (N. Jones, personal communication). Introduction of mutant 
p53 (codon 143, val to ala) had no detectable effect on the expression of Bcl-2 in A2780 
cells. Furthermore, induction of DNA damage did not appear to cause an accumulation 
of Bcl-2 in A2780/cp70 cells. If Bcl-2 does accumulate in response to DNA damage it 
may only be apparent at a time at which apoptosis is induced in A2780 cells and so a 72h 
time point may be more appropriate however no Bcl-2 accumulation was observed in 
these cells in response to cisplatin (N. Jones, personal communication).
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F igure 5.5 SDS-PAGE gel of protein from 4Gy irradiated (+) and unirradiated (-) 
A2780 (lanes 2 and 3), A2780/cp70 (lanes 4 and 5), A2780/mp53 (lanes 6 and 7) and 
A2780/v (lanes 8 and 9). The gel was Western blotted and probed with anti-human 
p53 and anti-human Bcl-2 antibodies. Positive control is a protein preparation from 
A2780 cells known to cross react with the anti-human p53 antibody. Protein sizes 
were confirmed using pre-stained molecular weight markers.
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5.8 Conclusions
A2780 cells were capable of undergoing apoptosis in response to cisplatin treatment 
as demonstrated by detection of non-random DNA fragmentation. As was observed in 
response to ionising radiation, these cells did not produce the DNA ladder on agarose 
gels following cisplatin treatment. This may indicate that the degradation of DNA to 
50kbp and 300-1000kbp fragments and the lack of DNA laddering is not agent specific. 
A2780 cells did not require the degradation of DNA to intemucleosomal fragments in 
order to die by apoptosis. Indeed they may be incapable of either producing these 
fragments or of surviving long enough after the initial apoptosis signal for further DNA 
degradation to occur.
It was clear from field inversion gel electrophoresis that A2780/cp70 cells underwent 
very little apoptosis as evidenced by the extremely low level of DNA degradation 
occurring in these cells. There was an unavoidable high degree of interexperimental 
variation in the quantitation of cisplatin-induced apoptosis. Nonetheless during any one 
experiment a lower degree of apoptosis was always observed in A2780/cp70 cells as 
compared with A2780 cells and the increased levels of apoptosis in the parental cell line 
were statistically significant albeit marginally when comparing equally damaging 
concentrations of cisplatin.
A slightly reduced level of apoptosis was observed in A2780/v cells as compared with 
the parental cell line. This may indicate that the transfection of the vector alone was 
capable of rendering the cells less sensitive to cisplatin-induced apoptosis at the time 
points examined. The level of cisplatin-induced apoptosis in A2780/mp53 cells however, 
was even further reduced, indicating a role for p53 in the sensitivity of A2780 cells to 
cisplatin and a role for dysfunctional, mutant p53 in the acquisition of cisplatin resistance 
in this cell line. A role for the loss of p53 function in the acquisition of cisplatin
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resistance was supported by the reduced apoptotic response of eight out of nine cisplatin 
resistant derivative lines of A2780 selected by multiple exposures of A2780 cells to 
increasing concentrations of cisplatin.
The measurement of apoptosis in the multiple step-selected cisplatin-resistant lines 
also revealed a possible means for determining the sequence of events which led from 
cisplatin exposure to cisplatin resistance. A2780/mcpl and A2780/mcp5 lost their 
apoptotic response with expansion in culture. The other multiply selected cisplatin 
resistant lines (with the exception of A2780/mcp7) all displayed similarly low levels of 
cisplatin-induced apoptosis both shortly after isolation and following expansion in 
culture. Presumably these cell lines had lost their apoptotic response at a time prior to 
A2780/mcpl and A2780/mcp5. Cell stocks of all of these lines were frozen at each stage 
of cisplatin exposure (D.A. Anthoney, personal communication). These cells could be 
examined for their responses to cisplatin-induced apoptosis in conjunction with other 
cellular events (such as loss of p53 function) in order to elucidate the chain of events 
leading to cisplatin resistance in this cell line model.
As alluded to above, A2780/mcp7 did not lose it’s apoptotic response to cisplatin 72h 
after exposure to the drug yet was resistant to cisplatin as measured by clonogenic assay. 
This suggests a different mechanism for cisplatin resistance in this derivative of A2780 to 
that operating in A2780/cp70 and in the other multiple step-selected cisplatin resistant 
cell lines.
The expression of one protein that could possibly be involved in loss of apoptosis in 
A2780/cp70 and A2780/mp53 was studied. The Bcl-2 protein which acts as a protection 
against apoptosis in some cell lines was found to be more highly expressed in 
A2780/cp70 cells than in A2780 cells. This protein may be involved in the reduced ability 
of A2780/cp70 cells to engage apoptosis however the cellular changes responsible for
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this increase in Bcl-2 expression are unknown. Ionising radiation resistance induced by 
the transfection of a mutant TP53 (codon 143, val to ala) did not involve an increase in 
Bcl-2 expression.
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CH APTER 6
Discussion
6.1 Summary of results
6.1.1 Development of assays to detect and quantitate apoptosis
Ionising radiation and cisplatin were used as DNA damaging agents to induce 
apoptosis within A2780 cell cultures in order to establish methodologies for the 
detection and quantitation of apoptosis. The most accurate and objective method for 
detecting apoptosis in A2780 cells was found to be field inversion gel electrophoresis of 
DNA. The DNA was obtained by lysing cells in pellets of low gelling temperature 
agarose. Apoptosis was quantitated in cell populations using fluorescent end-labelling of 
DNA fragments by TUNEL and propidium iodide staining. TUNEL utilises terminal 
DNA transferase to conjugate biotinylated nucleotides to the 3 ' -OH ends of DNA which 
can then be detected by binding of streptavidin-linked fluorescein. The total cellular 
DNA is stained with propidium iodide to allow visualisation of the cell cycle phases by 
FACS analysis. These cells, viewed by confocal microscopy, displayed cellular 
morphology characteristic of apoptotic cells: dense chromatin, pyknotic nuclei around 
the cell margin, apoptotic bodies budding from cells. In addition, cells displaying 
apoptotic morphology were also those which displayed increased green fluorescence due 
to TUNEL staining.
6.1.2 Apoptosis in A2780 cells
A2780 cells engaged apoptosis in response to DNA damage generated by both 
ionising radiation and cisplatin. The DNA of apoptotic A2780 cells underwent a process 
of non-random fragmentation, ubiquitous to apoptosis in other cell types (Oberhammer 
et al., 1993). The DNA degrades in response to the engagement of a programmed cell 
death pathway that controls the death of cells subjected to lethal doses of DNA
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damaging agents (Kerr et al., 1994). DNA fragments of two sizes were produced in 
association with apoptosis in A2780 cells; one of 50kbp and one of 300-1000kbp. The 
DNA did not fragment further to produce the DNA ladder on agarose gels subjected to 
electrophoresis. As mentioned above, apoptotic A2780 cells stained by TUNEL/PI 
displayed characteristic apoptotic morphology. These same TUNEL/PI-stained cells 
were analysed by flow cytometry. Maximal apoptosis occurred at either 72h or 96h after 
cisplatin treatment. Similar kinetics of apoptosis were observed after ionising radiation 
treatment.
6.1.3 Apoptosis in cisplatin resistant derivatives of A2780
Ionising radiation-induced apoptosis was reduced in the A2780/cp70 cell line 
compared to A2780 cells. Cisplatin-induced apoptosis was reduced in nine out of ten 
cisplatin resistant cell lines derived in vitro from A2780 cells. A2780/mcp7, which was 3- 
fold cisplatin resistant compared to the parental line, retained the ability to apoptose in 
response to cisplatin. This cell line also retained the p53-dependent, DNA damage- 
induced G1 arrest. These observations point to the acquisition of DNA-damage reistance 
by a mechanism other than loss of p53 function.
A higher level of Bcl-2 was observed in A2780/cp70 cells and this may contribute 
to the lack of apoptosis seen in this cell line however further analysis of the expression of 
other Bcl-2 and Bax family members would be required to elucidate the role of Bcl-2 in 
the loss of apoptosis in this cell line model. It is likely that upstream events may feed into 
the Bcl-2 pathway in order to effect the loss of apoptotic response in these cisplatin 
resistant derivatives of A2780 cells.
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6.1.4 The role of p53 in the apoptotic responses of A2780 cells
The role of p53 in ionising radiation- and cisplatin-induced apoptosis of A2780 
cells was investigated using a mutant TP53 (codon 143, val to ala)-transfected cell line, 
A2780/mp53. The control cell line for these experiments was a vector -transfected cell 
line, A2780/v. Transfection of the vector alone was found to cause a decrease in the level 
of apoptosis observed after treatment with ionising radiation however transfection with 
mutant p53 (codon 143, val to ala) precipitated a further decrease in the level of 
apoptosis observed. The level of cisplatin-induced apoptosis was found to vary between 
experiments however A2780/v cells did not have a consistently reduced apoptotic 
response as compared with the A2780 parental cell line. After equal doses of cisplatin 
A2780/mp53 cells underwent less apoptosis than A2780/v. Taken together, these results 
indicate a role for functional p53 in the ionising radiation- and cisplatin-induced 
apoptotic responses of A2780 cells.
6.2 Mechanisms of acquired resistance in A2780 cells
It would appear that p53 is involved in the cellular signalling leading from 
detection of DNA damage to the engagement of a programmed cell death pathway in 
A2780 cells. It has been demonstrated for other cell types, that wild type p53 is 
necessary for ionising radiation-induced apoptosis (Clarke et al., 1993; Lowe et al.,
1993). In addition, cells lacking endogenous wild type p53 do not arrest in G1 phase 
after ionising radiation treatment (Kuerbitz et al., 1992). Wild-type p53 protein 
accumulates in A2780 cells after cisplatin (Brown et al., 1993) or ionising radiation 
treatment (Mcllwrath et al., 1994). A2780 cells arrest in G1 phase and in G2 phase after 
treatment with ionising radiation and cisplatin (Brown et al., 1993). The G1 phase arrest 
in response to these agents and the sensitivity of the cells to them are dependent on wild-
type p53 function (Vasey et al., 1996; Mcllwrath et al., 1994). The acquisition of 
cisplatin resistance by A2780 cells also results in decreased expression of the p53- 
responsive gene, WAF1/CIP1 (Anthoney et al., 1996). A2780/cp70 cells accumulate p53 
protein in response to DNA damage but it does not function to produce an upregulation 
of y2 \WAFI/clpI mRNA and consequently does not induce a G1 phase cell cycle arrest. 
This lack of ^ 2 \WAFI/C1PI induction although observed in resistant cell lines may not be 
causative for loss of apoptosis. It has been shown that p:2 lWAF1/clPI is dispensible for 
oncogene-induced apoptosis in mouse embryo fibroblasts (Attardi et al., 1996).
The most direct effectors of apoptosis discovered to date appear to be the ced- 
3/ICE-like proteases or caspases. Currently ten of these proteins have been described, 
caspase-1 through caspase-10 (Martins and Eamshaw, 1997). In vitro studies have 
shown that a protease cascade involving the caspases acts to transduce apoptotic signals. 
As such, caspases are thought of as the ‘executioners’ of cell death as opposed to 
proteins such as p53 and the Bcl-2/Bax family members which appear to modulate the 
‘committment’ of a cell to becoming apoptotic. Overexpression of Bcl-2 or B c1-xl is 
capable of preventing the activation of the caspase cascade and inhibits hypoxia-induced 
apoptosis (Shimizu et al., 1996). Although A2780/cp70 was found to express more Bcl- 
2 than the parental cell line it would be necessary to know more about the expression of 
other Bcl-2/Bax family members in these cell lines before drawing any conclusions as to 
the possible influence of Bcl-2 on downstream events such as caspase activation.
Increased Bcl-2 protein was not observed in A2780/cp70 following ionising 
radiation treatment and has not been seen following treatment with cisplatin or Taxol (N. 
Jones, personal communication). The levels of three other Bcl-2 related proteins were 
also investigated in the A2780 and A2780/cp70 cell lines: B c1-x l , Bax and Bak. B c1-xl  
functions in a similar manner to Bcl-2 while Bax and Bak are pro-apoptotic proteins.
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Bcl-xLwas expressed at a higher level in A2780/cp70 cells than in the parental cell line 
and did not change after drug treatment. A 21kDa form of Bax appeared after cisplatin 
treatment in A2780 cells. This protein has been shown to promote apoptosis and it has 
been suggested that the ratio of this form of Bax to Bcl-2 may be an important 
modulator of apoptosis (Oltvai et al., 1993). Bak was expressed at a higher level in 
cisplatin-resistant cells and was also induced by cisplatin treatment.
Nine out of ten of the cisplatin resistant derivative cell lines of A2780 have reduced 
constituent levels of WAF1/CIP1 mRNA and a reduction in the DNA damage-induced 
G1 arrest. These lines also have a mutator phenotype (Table 6.1, summarised from 
Anthoney et al., 1996). It is these same cells that show a reduction in cisplatin-induced 
apoptosis (see section 5.6). A2780/mcp7 which was the only cisplatin resistant line not 
to lose its apoptotic response is also the only line that does not display the microsatellite 
instability phenotype. It is clear that the resistance mechanism in this cell line differs from 
that in the remainder of the lines examined in this study.
It is possible that acquired cisplatin resistance in A2780 cells arises due to the 
selection of cells with a mutator phenotype (RER+ phenotype). The RER+ phenotype is 
associated with a loss of mismatch repair. The RER+ phenotype observed in the panel of 
cisplatin resistant lines used in this study is associated with the loss of the mismatch 
repair protein hMLHl (Brown et al., 1997). MLH1 complexes with PMS2 and the 
MSH2/MSH6 complex to recognise and repair single base mispairs in DNA. These 
repair proteins have been found to bind with high affinity to a 1,2 diguanyl platinum 
intrastrand crosslink opposite to a single G:T mispair (Drummond et al., 1996). It is 
possible that the loss of hMLHl leads to loss of DNA damage-induced apoptosis.
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Table 6.1 Characteristics of cisplatin resistant A2780 cell lines, (summarised from 
Anthoney et al., 1996). Fold resistance, % cisplatin apoptosis and G1 arrest were 
determined as described in Chapter 5. RER status (Replication ERror, mutator 
phenotype) was determined by detection of microsatellite mutations and WAF1/CIP1 
mRNA levels were determined by Northern blot analysis using a WAF1/CIP1 cDNA 
probe standardised against a GAPDHprobe as described (Anthoney et al., 1996).
Cell line Fold
resistance
RER
status
% cisplatin 
apoptosis
G1 arrest Relative 
WAF1/CIP1 
mRNA level
A2780 1 - 22 ++ 1
A2780/CP70 5 + 1 - 0.29
A2780/MCP1 1.5 + 4 - 0.52
A2780/MCP2 3.5 + 2 - 0.55
A2780/MCP3 5 + 1 - 0.32
A2780/MCP4 4 + 1 - 0.58
A2780/MCP5 2 + 8 + 0.33
A2780/MCP6 2.5 + 7 - 0.49
A2780/MCP7 3 - 20 + 0.95
A2780/MCP8 3.5 + 1 +/- 0.66
A2780/MCP9 1.5 + 1 + 0.56
How this signalling mechanism may interact with p53 is unclear. The defects in 
either p53 function or in mismatch repair suggest that the two mechanisms may operate 
as part of the same pathway in normal cells. The observations in A2780/mcp7 and 
A2780/mcp8 are anomalous with the rest of the data. In the case of A2780/mcp7, MLH1 
expression is lost while p53 function remains intact. A2780/mcp8 cells retain MLH1 
expression and mismatch repair activity (J. Drummond, personal communication) but 
display microsatellite instability and have lost the p53-dependent apoptotic response. 
They do, however retain a residual DNA damage-induced G1 arrest. It could be 
envisaged that following cisplatin-induced DNA damage, a signalling cascade is set in
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action which encompasses recognition of complex lesions by mismatch repair proteins, 
a p53-dependent appraisal of the extent of the damage precipitating a decision to live or 
die and a subsequent signal to either cell cycle arrest and repair or to enter a 
programmed cell death pathway leading to apoptosis.
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